All articles tagged: Hematology-Oncology
MedScape
30 May at 04.38 AM
ASCO Advises on CDK4/6 Inhibitors for Breast CancerASCO provided guidance on the use of abemaciclib and ribociclib in the adjuvant setting for patients with stages II and III breast cancer. |
MedScape
29 May at 08.59 AM
Diabetes May Affect Breast Cancer Care for Some WomenLow-income women with diabetes were less likely to receive adjuvant radiotherapy and chemotherapy to treat breast cancer compared with those without diabetes. |
MedScape
28 May at 06.08 PM
US FDA Approves Amgen's Biosimilar to AstraZeneca's Rare Blood Disorder TreatmentThe U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood disorder treatment Soliris. |
MedScape
28 May at 08.50 AM
Obesity and Cancer: Untangling a Complex WebAlthough more than 40% of cancers are considered obesity-related, excess weight is often just a contributing risk factor, leaving uncertainty about the role weight plays in cancer risk. |
MedScape
27 May at 05.32 AM
How Metabolic Syndrome, Obesity Impact Breast Cancer RiskNew data from the Women's Health Initiative revealed that metabolic syndrome and obesity each have different associations with breast cancer incidence and mortality risk in postmenopausal women. |
MedScape
24 May at 09.13 AM
The ASCO Annual Meeting Starts Next Week in ChicagoAbout 45,000 people are expected in Chicago for the world's largest clinical oncology meeting. |
MedScape
24 May at 09.07 AM
Canadian Colorectal Cancer Screening Programs HeterogeneousAlthough provincial screening programs include the most essential elements, many could improve aspects of quality, efficacy, and impact, researchers said. |
MedScape
24 May at 07.52 AM
Urine Test Could Prevent Unnecessary Prostate BiopsiesProstate cancer screening tests lack specificity in detecting higher-grade tumors, but a new urine test could help detect aggressive cancers. |
MedScape
24 May at 04.16 AM
Tucatinib-Trastuzumab Benefit 'Remarkable' in HER2+ Mets CRCThe dual HER2 blockade regimen is bringing substantial clinical benefits to a population with few therapeutic options. |
MedScape
24 May at 03.06 AM
|
MedScape
24 May at 02.09 AM
Exemestane Plus Ovarian Suppression Best in Early ILCNew data add to the body of evidence favoring the aromatase inhibitor therapy plus ovarian suppression over tamoxifen for premenopausal women with early invasive lobular carcinoma. |
MedScape
23 May at 03.06 AM
Is Vaginal Estrogen Safe in Breast Cancer Survivors?Vaginal estrogen therapy appears to be safe after early breast cancer in patients with HR-negative tumors and those with HR-positive tumors concurrently treated with tamoxifen, new data suggest. |
MedScape
22 May at 09.06 AM
Statin Use May Extend Life for Breast Cancer PatientsA recent study discovered that breast cancer patients who took statins, medications that lower cholesterol, had notably lower mortality rates compared with those who did not use these drugs. |
MedScape
22 May at 08.33 AM
Exercise Improves Sexual Health in Metastatic Breast CancerExercise can help improve sexual health in women with metastatic breast cancer and should be a key component of care, researchers said. |
MedScape
22 May at 07.03 AM
Chemoradiotherapy or RT in Lower Risk Early Cervical Cancer?A study found no significant differences in survival with postoperative chemoradiotherapy vs RT alone in patients who have early-stage cervical cancer without high-risk factors. |
MedScape
21 May at 08.58 AM
Liposomal Irinotecan for Pancreatic Cancer: Is It Worth It?Some oncologists have called the regimen a new standard of care, while others aren't convinced that the new first-line pancreatic cancer regimen is worth the high cost. |
MedScape
21 May at 08.00 AM
ART Safe for Breast Cancer Survivors With BRCA1/2 MutationsNew data presented at ESMO suggest that assisted reproductive techniques are safe for women with BRCA1/2 mutations who have been treated for breast cancer. |
MedScape
21 May at 06.33 AM
FDA Grants Withdrawal of Infigratinib for CholangiocarcinomaThe drug company voluntarily requested the withdrawal of infigratinib, citing challenges enrolling patients for the required confirmatory postmarketing trials. |
MedScape
21 May at 04.50 AM
Urine Tests Could Be 'Enormous Step' in Diagnosing CancerEmerging science suggests urine tests could offer a convenient, cost-effective way to spot hard-to-detect cancers. |
MedScape
21 May at 03.19 AM
ADCs for Breast Cancer: Clear Benefits, Manageable RisksADCs are rapidly changing the treatment landscape for patients with metastatic breast cancer, with the agents demonstrating improved efficacy and manageable risks. |
MedScape
21 May at 02.54 AM
Cancer in Canada: Increasing Cases, Decreasing DiagnosesThe number of cancer cases and deaths in Canada will increase in 2024 and beyond as rates of cancer diagnosis and cancer-related mortality will decline. |
MedScape
20 May at 08.38 AM
Gene Panel Predicts Early HER2+ Breast Cancer PrognosisPatients with early-stage HER2+ breast cancer could soon be offered less intensive treatment based on the results of a 27-gene panel, following findings from a meta-analysis. |
MedScape
20 May at 07.36 AM
UK's Infected Blood Scandal Could and Should Have Been Avoided, Inquiry FindsAn infected blood scandal in Britain was no accident but the fault of doctors and a succession of governments that led to 3,000 deaths and thousands more contracting... |
MedScape
20 May at 05.32 AM
No Improvement in OS With Atezolizumab in Relapsing TNBCEarly relapsing disease has again shown the limitations of immunotherapy in triple-negative breast cancer after a trial found no overall survival benefit with the drug. |
MedScape
17 May at 08.39 AM
CDH1 Linked With New Hereditary Breast Cancer SyndromeData suggest the value of performing the CDH1 test on women under age 45 years, said a researcher. |
MedScape
17 May at 07.53 AM
Outside the Guidelines: Prostate Cancer Screening OverusedMen in their 70s and 80s report receiving prostate cancer screening, even though guidelines recommend against it. |
MedScape
17 May at 07.36 AM
'Practice Changing' Trial Guides Prostate Cancer TherapyAdding hormone treatment to radiotherapy in low-risk prostate cancer had no significant benefit, but 2 years hormone treatment was superior to 6 months in higher risk tumours. |
MedScape
17 May at 06.00 AM
Genetic Testing Low in Castration-Resistant Prostate CancerMost men with mCRPC in the United States do not receive recommended genetic testing for relevant mutations, suggesting efforts are needed to address barriers to testing. |
MedScape
16 May at 06.20 PM
FDA Approves Tarlatamab for Extensive-Stage SCLCContinued approval of the first-in-class bispecific T-cell engager (BiTE) may depend on proof of clinical benefit. |
MedScape
16 May at 05.26 PM
No Improvement in OS With Atezolizumab in Relapsing TNBCEarly relapsing disease has again shown the limitations of immunotherapy in triple-negative breast cancer after a trial found no overall survival benefit with the drug. |
MedScape
16 May at 09.57 AM
Why Do Certain Patients With Pancreatic Cancer Skip Surgery?Weight loss during preoperative chemotherapy was one factor associated with reduced odds of undergoing surgical resection for pancreatic cancer. |
MedScape
16 May at 07.05 AM
FDA Broadens Breyanzi's Follicular Lymphoma IndicationThe overall response rate to the CAR T therapy was 95.7% in phase 2 testing. |
MedScape
15 May at 08.46 AM
Higher Risk Breast Cancer Screening: Which Test to Use?Decisions about who can benefit from additional screening and what screening modality is most appropriate are complex. |
MedScape
14 May at 10.10 AM
Skipping Axillary Lymph Node Dissection in Breast Cancer?Axillary recurrence was rare among patients who skipped standard axillary lymph node dissection after being downstaged to node-negative disease, a recent analysis found. |
MedScape
14 May at 09.42 AM
Breast Cancer Rates Skyrocketing in Young Canadian WomenThe high incidence of breast cancer in women younger than 40 years may warrant clinical vigilance. |
MedScape
13 May at 07.19 AM
Hypofractionated RT Limits Toxic Effects in Cervical CancerPatients undergoing post-surgery radiotherapy plus chemotherapy may benefit from a hypofractionated regimen to limit toxicities, a new study suggested. |
MedScape
13 May at 07.09 AM
Merck Stops Testing Combo Drug for Skin Cancer as More Patients DiscontinueMerck said on Monday it had discontinued an experimental combination treatment testing a new type of immunotherapy in patients with a severe form of skin cancer after side... |
MedScape
10 May at 08.30 AM
US County-Level Study Shows Benefits of PSA ScreeningA recent analysis found that US counties with higher rates of PSA screening had lower rates of metastatic prostate cancer and prostate cancer mortality in subsequent years. |
MedScape
09 May at 07.07 AM
More Is Not Always Better: Outdated Dosing in Breast CancerA new survey highlighted that using the maximum tolerated dose in metastatic breast cancer leads to significant treatment-related toxicities and reducing that dose can improve quality of life. |
MedScape
08 May at 09.41 AM
Do or Die: Community Oncology Needs More FellowsCommunity oncology practices face challenges in attracting oncology fellows, highlighting the need for more fellows to ensure long-term sustainability. |
MedScape
08 May at 08.18 AM
Health-Related Needs Up Mortality Risk in Cancer SurvivorsNew data showed that health-related social needs and financial difficulties are associated with a higher risk of mortality in cancer survivors. |
MedScape
07 May at 09.37 AM
Do Patients Benefit from Cancer Trial Participation?A recent meta-analysis found that overall investigational drugs demonstrate modest survival benefits and greater toxicities for patients participating in cancer clinical trials. |
MedScape
07 May at 09.05 AM
Online Skin Cancer Depictions on Darker Skin Tones LimitedFewer than half of images on different government and organization websites studied showed patients with darker skin tones. |
MedScape
06 May at 07.24 AM
Terminal Cancer: What Matters to Patients and CaregiversPatients with advanced cancer and their caregivers often align on goals of care, except when it comes to decisions about costs, a new survey found. |
MedScape
06 May at 05.08 AM
Do No Harm: What Smoldering Myeloma Teaches UsManni Mohyuddin, MD, highlights how he treats smoldering multiple myeloma. |
MedScape
03 May at 08.30 AM
Digital Health Sector Slowed Down in 2023Although the average amount raised in European funding rounds decreased, the number of investors increased by nearly one quarter. |
MedScape
03 May at 08.04 AM
MicroRNAs Predict Pancreatic Cancer Risk Years in AdvanceExpression levels of several microRNAs in plasma samples can help predict the onset of pancreatic cancer up to 5 years prior to clinical diagnosis. |
MedScape
03 May at 12.16 AM
What's Driving Higher Breast Cancer Deaths in Black Women?Despite improvements in breast cancer screening and treatment, Black women experience higher death rates and more aggressive forms of the disease than White women. |
MedScape
02 May at 08.36 AM
Potential Cure for Early BRCA-Mutated Breast Cancer?A small trial found "a remarkable 100% of patients were still alive at 36 months" after receiving olaparib plus standard chemotherapy. |
MedScape
01 May at 12.43 PM
Cervical Cancer Screening: US PCPs Unclear on Best PracticesA new survey found that most US clinicians may not be following the American Cancer Society's cervical cancer screening guidelines, which are based on the most up-to-date evidence. |
MedScape
01 May at 06.34 AM
J&J Advances $6.475 Billion Settlement Of Talc Cancer LawsuitsJohnson & Johnson is moving forward with a $6.475 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and other talc products... |
MedScape
01 May at 06.34 AM
J&J Advances $6.48 Billion Settlement Of Talc Cancer LawsuitsJohnson & Johnson said on Wednesday it is moving forward with a $6.48 billion proposed settlement of tens of thousands of lawsuits alleging that its baby powder and... |
MedScape
01 May at 05.18 AM
Tool May Help Prioritize High-Risk Patients for HysteroscopyA new nomogram is intended to identify patients at high risk for endometrial cancer and prioritize them in the hysteroscopy waiting list. |
MedScape
30 April at 04.36 PM
Routine Breast Cancer Screening Should Start at 40: USPSTFThe USPSTF has shifted to a stronger recommendation to start mammograms earlier, noting a need for more research on breast cancer for Black and older women and those with dense breasts. |
MedScape
30 April at 10.47 AM
Could Aspirin Help Treat Breast Cancer?A new study found that taking aspirin as adjuvant therapy does not improve outcomes for patients with high-risk nonmetastatic breast cancer. |
MedScape
30 April at 09.46 AM
Stereotactic Radiosurgery to Treat 15-Plus Brain Metastases?A large study supports the use of stereotactic radiosurgery in patients with 15 or more brain metastases, finding improved cognitive outcomes and comparable survival to whole brain radiation. |
MedScape
29 April at 09.00 AM
Is Immunotherapy for Cancer Safe in Pregnancy?No adverse pregnancy, foetal, or newborn outcomes found compared with other anticancer agents except for two immunotherapies given together. |
MedScape
29 April at 07.23 AM
New Trials in Prostate Cancer: Could Your Patient Benefit?Perhaps one of your patients could benefit from a clinical trial that has recently opened in prostate cancer. |
MedScape
26 April at 02.04 PM
EMA Approves Factor VIII Deficiency Clotting DrugEuropean Union marketing authorization recommended for Altuvoct for hemophilia A caused by factor VIII deficiency. |
MedScape
26 April at 11.12 AM
Europe Recommends Three Cancer DrugsThe European Medicines Agency has recommended Fruzaqla, Truqap, and Eribulin Baxter for use in the treatment of specific colorectal and breast cancers. |
MedScape
26 April at 09.06 AM
Definitive Therapy Ups Survival in Brain-Only Mets NSCLCDefinitive treatment to the primary site improves overall and cancer-specific survival among patients with brain-only NSCLC metastases, a recent retrospective study shows. |
MedScape
25 April at 08.53 AM
How to Improve Radiotherapy Decisions in Endometrial CancerRadiotherapy decisions should be made using refined genomic guidance, as recommended by 2021 updated international guidelines, to better identify patients with molecularly aggressive disease. |
MedScape
25 April at 05.39 AM
Timing Is Everything: CAR T for Follicular LymphomaCAR T-cell therapy is the best option for patients with relapsed/refractory follicular lymphoma, even though it comes with serious side effects. |
MedScape
24 April at 09.01 AM
Is the FDA Pausing More Cancer Trials? It's Hard to TellClinical trial holds delay therapies getting to market and may be on the rise in oncology. But there's a lot the public doesn't know about how often these holds happen and why. |
MedScape
23 April at 11.01 AM
Europe Approves Paroxysmal Nocturnal Hemoglobinuria DrugThe factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal nocturnal hemoglobinuria with residual hemolytic anemia on standard therapy. |
MedScape
23 April at 09.02 AM
FDA Approves New Bladder Cancer DrugThe first-in-class agent is approved alongside bacillus Calmette-Guérin to treat certain non–muscle-invasive bladder cancers that do not respond to bacillus Calmette-Guérin alone. |
MedScape
23 April at 08.20 AM
Is Osimertinib Better Alone or With Chemotherapy in NSCLC?A new study reveals that baseline EGFR mutations may be key to making the decision in the frontline setting. |
MedScape
23 April at 07.20 AM
Few Cancer Survivors Meet ACS Nutrition, Exercise GuidelinesOnly 4% of cancer survivors reported adhering to four key healthy lifestyle practices endorsed by the American Cancer Society. |
MedScape
23 April at 05.47 AM
PSA Detectable After Radical ProstatectomyFollowing radical prostatectomy, however, approximately 20%-40% of patients with localized disease will experience biochemical recurrence. |
MedScape
22 April at 09.00 AM
Immunotherapy for Renal-Cell Carcinoma Saves LivesA 5-year randomised, placebo-controlled trial of pembrolizumab found a 38% reduction in death vs placebo. |
MedScape
22 April at 06.19 AM
Has Immunotherapy Found Its Place in Pancreatic Cancer?A new study suggested that adding nivolumab to neoadjuvant treatment improves outcomes in patients with borderline resectable pancreatic cancer. |
MedScape
22 April at 04.45 AM
Alectinib Approved for ALK-Positive Adjuvant NSCLCThe approval makes alectinib the first ALK inhibitor approved for early-stage NSCLC. |
MedScape
19 April at 09.17 AM
New Screening Protocol May Improve Prostate Cancer DetectionHowever, it's not yet clear whether a new three-phase screening intervention, which incorporates PSA test, a four-kallikrein panel, and MRI, will reduce prostate cancer mortality. |
MedScape
19 April at 05.26 AM
Why Lung Cancer Screening Is Not for EveryoneMany patients undergo lung cancer screening despite having a higher likelihood of experiencing harm rather than benefit. |
MedScape
18 April at 06.39 PM
US FDA Mandates Label Updates on CAR-T Cancer TherapiesThe U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the... |
MedScape
18 April at 07.24 AM
Cancer Stage vs Mortality Endpoints in Screening Trials?In clinical trials of cancer screening, the incidence of late-stage cancer works as well as cancer-specific mortality as an endpoint for some cancers but not others. |
MedScape
18 April at 05.27 AM
How Medicare Reimbursement Trends May Affect Breast SurgeryNew data showed that Medicare reimbursement for breast cancer surgeries has declined significantly in recent years. |
MedScape
18 April at 01.34 AM
Can DNA Tests Promote Colorectal Cancer Screening?Colorectal cancer screening remains inadequate in France, but DNA tests could enable screening through a simple blood test or stool analysis. |
MedScape
17 April at 10.39 AM
Panel: MRD Tests May Speed Myeloma Tx ApprovalsODAC unanimously backed the use of highly sensitive tests that check for minimal residual disease to speed up drug approvals for multiple myeloma. |
MedScape
17 April at 09.19 AM
Certain Women May Face Higher Risk for Second Breast CancerYoung breast cancer survivors with a germline pathogenic variant or who are initially diagnosed with in situ disease have more than a fourfold higher risk for a second primary breast cancer. |
MedScape
17 April at 09.16 AM
Microbial Signature of KRAS-Mutated CRC IdentifiedResearchers analyzed gut microbiota from KRAS-mutated and KRAS wild-type colorectal cancer to assess the link between disruptions in the gut microbiome and KRAS mutations in the disease. |
MedScape
17 April at 07.53 AM
New Agent Shows Early Promise in Triple-Class Refractory MMWith linvoseltamab and other bispecific antibodies inducing deep and durable responses, there might finally be a go-to option for multiple myeloma patients resistant to mainstay treatments. |
MedScape
16 April at 09.14 AM
Most Targeted Cancer Drugs Lack Substantial Clinical BenefitOnly a minority of genome-targeted cancer drugs recently approved in the United States demonstrate significant clinical benefits to patients, a new analysis found. |
MedScape
15 April at 07.29 AM
ALL: Which Life-Saving Tx Is Best?New treatments like bispecific antibodies and CAR T-cell therapy have helped many patients with relapsed/refractory acute lymphoblastic leukemia live longer but which is best? |
MedScape
15 April at 05.09 AM
Monitoring ctDNA Predicts HER2+ Cancer Treatment ResponseTracking a patient's circulating tumor DNA (ctDNA) can offer insight into how well-targeted therapies work in the early stages of treatment for HER2-positive cancers. |
MedScape
15 April at 02.56 AM
Is Axillary Surgery in Early Breast Cancer on Its Way Out?Omitting axillary surgery in patients with early breast cancer who had sentinel-node metastases and underwent surgery and radiotherapy did not compromise survival outcomes, new data show. |
MedScape
12 April at 09.26 AM
Oncologists Voice Ethical Concerns Over AI in Cancer CareA survey of oncologists highlighted ethical issues over the use of AI in cancer care and revealed some contradictory views about how best to integrate these tools. |
MedScape
12 April at 08.21 AM
No Routine Cancer Screening Option? New MCED Tests May HelpEarly data suggest that several new multicancer early detection tests can identify a range of cancers that lack routine screening options. |
MedScape
12 April at 07.18 AM
Ovarian Cancer: Another Promising Target for Liquid BiopsyA blood test to screen for ovarian cancer is one of many new liquid biopsy assays being evaluated to screen for cancer. |
MedScape
11 April at 10.56 AM
More Adults Are Participating in Cancer Clinical TrialsNew estimates suggest that more adults with cancer are participating in cancer trial research, especially at National Cancer Institute–designated centers, but overall enrollment rates remain low. |
MedScape
11 April at 10.14 AM
What to Know About the Next-Gen FIT for CRC ScreeningSeveral new multitarget stool-based screening tests on the horizon may improve early colorectal cancer detection, according to findings from recent analyses. |
MedScape
11 April at 08.39 AM
ImPrint Identifies Treatment for Patients With Breast CancerData from the ongoing phase 2 trial show that clinicians can use ImPrint, an immune-related biomarker, to identify breast cancer patients who are likely to respond to neoadjuvant immunotherapy. |
MedScape
10 April at 08.49 AM
Liquid Biopsy Shows Promise in Detecting Pancreatic CancerA new screening test raises the possibility of catching pancreatic cancer earlier, when tumors can be removed, and patients cured. |
MedScape
10 April at 06.13 AM
Combo Therapy Prolongs Survival in Gastric Cancer PatientsThe overall survival advantage held regardless of PD-L1 status in patients receiving the first-line combination of cadonilimab and standard chemotherapy. |
MedScape
10 April at 05.08 AM
Intermediate Endpoints Predict Breast Cancer SurvivalData suggest that intermediate clinical endpoints can serve as surrogate endpoints for overall survival in patients with early-stage breast cancer receiving adjuvant therapy. |
MedScape
08 April at 02.51 PM
FDA Expands Enhertu Indication to HER2-Positive Solid TumorsThe move from the FDA marks the first tumor-agnostic approval of a HER2-directed therapy and antibody drug conjugate. |
MedScape
08 April at 02.02 PM
Abecma Approved for Earlier Lines in R/R Multiple MyelomaThe drug manufacturers report a complete response rate of 39% with idecabtagene vicleucel (Abecma) vs 5% with standard regimens. |
MedScape
08 April at 12.56 PM
Less Than 50% of Accelerated Approvals Show Clinical BenefitA new study looks at 5-year outcomes of cancer drugs that were given accelerated approvals. |
MedScape
08 April at 05.56 AM
Should Opioids Be Used for Chronic Cancer Pain?While prescription opioids are commonly used to treat moderate to severe pain in cancer patients during treatment, there is less clear guidance on using opioids after treatment ends. |
MedScape
08 April at 02.56 AM
Eliminating H pylori Lowers CRC Incidence, Mortality RiskTwo weeks of antibiotics to eradicate the carcinogenic bacteria reduce the risk for CRC incidence and mortality, a new analysis suggested. |
MedScape
05 April at 03.05 AM
Oncology Practice and Lab to Pay $4 Million in Kickback CaseSan Antonio–based healthcare providers have agreed to pay over $4 million in civil settlements to resolve allegations of violating the False Claims Act through an unlawful kickback arrangement. |
MedScape
04 April at 08.15 AM
'Nothing Rivaled This': Navigating the Cancer Drug ShortageBecause this platinum drug shortage crisis won't be the last, oncology practices need to be better prepared to tackle future problems. |
MedScape
04 April at 07.11 AM
Less Neck Radiation Effective in Early Nasopharyngeal CancerOmitting radiation to the lower-neck region in patients with early-stage nasopharyngeal cancer provided similar survival outcomes and reduced long-term toxicity compared to whole-neck irradiation. |
MedScape
03 April at 05.32 PM
Sanofi to Settle 4,000 Zantac Cancer Lawsuits in US State CourtsSanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on... |
MedScape
03 April at 07.26 AM
Polygenic Risk Scores Improve Breast Cancer ScreeningA Finnish study shows that adding polygenic risk scores to positive family histories and breast cancer-associated gene mutations improves risk stratification for breast cancer screening. |
MedScape
03 April at 03.23 AM
Certain Pesticides Linked With Risk for Pancreatic CancerThe incidence of pancreatic adenocarcinoma has been increasing steadily for more than 30 years. |
MedScape
02 April at 09.10 AM
FDA OKs Danicopan for Extravascular Hemolysis in PNHA tablet has been approved for a common complication during treatment for a rare blood disorder. |
MedScape
02 April at 08.25 AM
New Trials in Prostate Cancer: Could Your Patient Benefit?Perhaps one of your patients could benefit from a clinical trial that has recently opened in prostate cancer. |
MedScape
02 April at 07.21 AM
It Takes a Village: Treating Patients for NSCLC Brain MetsTreatment decisions for patients with NSCLC metastasized to the brain should involve a multidisciplinary team, considering factors such as immunotherapy efficacy and optimal treatment sequences. |
MedScape
01 April at 07.59 AM
Addressing Sexual Dysfunction in Women's CancersMany women with cancer want advice for managing sexual function issues, and clinicians are tuning in, new studies suggest. |
MedScape
01 April at 06.10 AM
'Quad Shot' RT, Immunotherapy Improves Local Control in HNCA palliative Quad Shot radiotherapy regimen alongside concurrent immunotherapy can improve local control in symptomatic patients with head and neck cancer but may not improve overall survival. |
MedScape
29 March at 07.07 AM
Active Surveillance Doesn't Increase Malpractice RiskPhysicians should feel reassured in recommending active surveillance as a management strategy for low-risk cancers, as no successful malpractice cases related to this approach have been found. |
MedScape
29 March at 07.07 AM
Active Cancer Surveillance Doesn't Increase Malpractice RiskPhysicians should feel reassured in recommending active surveillance as a management strategy for low-risk cancers, as no successful malpractice cases related to this approach have been found. |
MedScape
28 March at 07.42 AM
ASCO Releases Vaccination Guidelines for Adults With CancerA recent ASCO guideline provides recommendations for routine and additional vaccinations for adults with solid tumors or hematologic malignancies as well as their household contacts. |
MedScape
28 March at 06.35 AM
Can Minimally Invasive Surgery Match Open in Ovarian Cancer?Minimally invasive surgery for ovarian cancer does not appear to affect survival compared with open surgery when tumors are completely removed. |
MedScape
28 March at 04.19 AM
French Cohort Shows Good Prognosis of MSI Colorectal CancerNonmetastatic microsatellite instability colorectal cancers nevertheless entailed a high risk for recurrence in stage III, especially when not treated with adjuvant chemotherapy. |
MedScape
28 March at 03.01 AM
Amivantamab Offers Post-Progression Benefit in EGFRm NSCLCEven if patients with EGFR-mutated lung cancer progress on amivantamab plus chemotherapy, there is a survival benefit over chemotherapy alone, follow-up analyses of PAPILLON and MARIPOSA-2 showed. |
MedScape
28 March at 02.33 AM
Lung Cancer Screening Unveils Hidden Health RisksScreening for lung cancer can identify more than lung malignancies. |
MedScape
27 March at 08.23 AM
Tarlatamab Shows Promise in Tackling Previously Treated SCLCThe investigational drug led to encouraging overall survival and intracranial disease control in patients with small-cell lung cancer, longer-term trial data suggested. |
MedScape
27 March at 07.12 AM
Novocure's Device Shown to Slow Cancer Progression in the Brain in TrialNovocure's therapy met the main goal of a late-stage trial of slowing the progression of cancer to the brain in patients with a type of lung cancer, the company said on... |
MedScape
27 March at 07.12 AM
Novocure's Lung Cancer Therapy Succeeds in Late-stage TrialNovocure said on Wednesday that its cancer therapy met the main goal of a late-stage trial testing it as a treatment for a type of lung cancer. |
MedScape
26 March at 06.26 AM
Black Women More Likely to Die From Endometrial CancerNew research confirms racial disparities in survival outcomes and representation in clinical trials among Black and White women with a common subtype of endometrial cancer. |
MedScape
26 March at 04.59 AM
Lung Cancer Screening Unveils Hidden Health RisksScreening for lung cancer can detect other health issues and can provide information on three of the top ten causes of death. |
MedScape
26 March at 03.35 AM
Subcutaneous Immunotherapy: Better Life for Cancer PatientsAdministering immunotherapy via subcutaneous infections could save clinicians time and money and patients may prefer it. |
MedScape
25 March at 02.16 PM
Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC?A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%. |
MedScape
25 March at 01.39 PM
Continued Benefit, More Toxicity With Osimertinib-ChemoPatients with advanced EGFR-mutated NSCLC who were given osimertinib plus chemotherapy up front continue to show improved outcomes after initial progression, suggests ongoing trial data. |
MedScape
25 March at 07.49 AM
FDA Grants Mirvetuximab Full Approval for Ovarian CancerMirvetuximab soravtansine-gynx (Elahere) is approved for patients with folate receptor–alpha positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. |
MedScape
25 March at 07.29 AM
Regeneron's Blood Cancer Therapy Faces Setback as FDA Raises Trial ConcernsRegeneron Pharmaceuticals said on Monday the U.S. FDA has declined approval for its blood cancer therapy for two forms of lymphoma on concerns over the progress of ongoing... |
MedScape
22 March at 01.29 PM
Few Childhood Cancer Survivors Get Recommended ScreeningsCancer survivors who were older at diagnosis were more likely to follow cancer screening guidelines, whereas those who were younger were more likely to get heart tests. |
MedScape
22 March at 10.19 AM
EU Backs First Oral Monotherapy for Adults With PNHThe European Medicines Agency has recommended Fabhalta for treating paroxysmal nocturnal hemoglobinuria after reviewing clinical trial results. |
MedScape
22 March at 07.18 AM
Diarrhea in Cancer Therapies — Part 1: ChemotherapeuticsA gastroenterologist and oncologist recently reviewed the appropriate assessment and treatment of patients with chemotherapy-associated diarrhea. |
MedScape
22 March at 07.04 AM
Predicting Risk for Secondary Leukemia after PARPi TherapyA new study pinpointed potential predictive factors for secondary myelodysplastic syndrome or acute myeloid leukemia after PARP inhibitor therapy in women with ovarian cancer. |
MedScape
22 March at 06.19 AM
Upfront Low-Dose Radiation Improves Advanced SCLC OutcomesResearchers added low-dose radiation to standard first-line treatment for extensive-stage small cell lung cancer to extend treatment benefits. |
MedScape
22 March at 03.02 AM
Sarcopenia Predicts Feeding Tube Placement in OPSCC PatientsIdentifying sarcopenia early in patients with oropharyngeal squamous cell carcinoma can help predict the need for feeding tube placement. |
MedScape
22 March at 03.02 AM
Sarcopenia May Predict FT Placement in Patients With OPSCCIdentifying sarcopenia early in patients with oropharyngeal squamous cell carcinoma can help predict the need for feeding tube placement. |
MedScape
21 March at 06.55 AM
Merck Combination Treatment for Lung Cancer Fails Late-stage StudyMerck said on Thursday a combination of two of its cancer drugs failed to meet the main goals of a late-stage study evaluating it as an initial treatment for a type of lung... |
MedScape
21 March at 05.08 AM
CHIP: The Silent Threat Steps Into the LimelightAs CHIP is better understood, its cardiovascular and oncological risks are more clearly defined, along with what to do about them, say experts. |
MedScape
21 March at 05.02 AM
New Transparent AI Predicts Breast Cancer 5 Years OutThe model's easier-to-understand process marks an important milestone in the quest to bring AI to bedside in a meaningful way. |
MedScape
21 March at 01.45 AM
Myeloma: FDA Advisers Greenlight Early CAR-TAn FDA advisory panel endorsed earlier use of CAR-T therapies to treat multiple myeloma but emphasized the importance of informing patients about potential risks associated with these treatments. |
MedScape
20 March at 07.55 AM
Non-Radical Surgery a Win-Win for Early Cervical CancerNew data from a prospective study support non-radical surgery (simple hysterectomy or cone biopsy) for early-stage low-risk cervical cancer. |
MedScape
20 March at 07.07 AM
Bristol Myers' Opdivo-Yervoy Combo Meets Main Goal in Liver Cancer TrialBristol Myers Squibb said on Wednesday a combination of Opdivo and Yervoy met the main goal of a late-stage study evaluating it as an initial treatment for a type of liver... |
MedScape
20 March at 06.59 AM
Remarkable Patients Inspired Father of Cancer ImmunotherapyThe father of cancer immunotherapy, Steven A. Rosenberg, reflects on the patients who inspired his groundbreaking research. |
MedScape
20 March at 06.49 AM
Secondary Cancers Post CAR T Therapy: A Concern?An analysis of the FAERS database found the incidence of secondary cancers following CAR T therapy represented 4.3% of all adverse events; however, only 0.1% were secondary T-cell malignancies. |
MedScape
20 March at 05.13 AM
FDA Approves Ponatinib for Upfront Ph+ ALLThis is the first targeted treatment approved for upfront use in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. |
MedScape
19 March at 08.51 AM
Can ChatGPT Help Manage Gynecologic Cancers?ChatGPT accurately answers common questions regarding gynecologic cancers but falls short in providing treatment recommendations, two separate studies found. |
MedScape
19 March at 08.42 AM
De-escalating Therapy for Oropharynx Squamous Cell CarcinomaThree new studies exploring treatment de-escalation of HPV-associated oropharynx squamous cell carcinoma added to data showing it's possible to reduce toxicity without jeopardizing oncologic outcomes. |
MedScape
19 March at 06.27 AM
Why a New Inhalable Lung Cancer Treatment Is So PromisingStudy showed that exosomes (tiny spheres released by cells) can deliver potent immunotherapy to lung cancer tumors. |
MedScape
19 March at 03.31 AM
RUBY: 'A Huge Win' for Patients With Endometrial CancerThe RUBY trial shows that adding an immune checkpoint inhibitor to chemotherapy improved overall survival by over 1 year for women with advanced or recurrent endometrial cancer. |
MedScape
18 March at 12.05 PM
QOL Not Harmed With Add-On Pembrolizumab in Cervical CancerAdding pembrolizumab to concurrent chemoradiotherapy does not affect quality of life in patients with high-risk locally advanced cervical cancer, new data show. |
MedScape
18 March at 09.00 AM
Does Vitamin D Protect Against Breast Cancer?A review article surveys the literature and considers dietary supplementation to achieve optimal vitamin D levels. |
MedScape
18 March at 03.44 AM
BCI Registry Improves Breast Cancer Treatment DecisionsAfter using the BCI test assay, physicians adjusted their treatment recommendations for patients with hormone receptor–positive breast cancer, according to a new study. |
MedScape
15 March at 02.26 PM
FDA Approves First CAR T-Cell Therapy for rrCLL, rrSLLThe accelerated approval for liso-cel was based on findings showing 20% of patients achieved a complete response from a one-time infusion after at least two prior lines of therapy. |
MedScape
15 March at 06.03 AM
Gilead CAR-T Cancer Therapy Capacity to Quadruple by 2026Gilead Sciences will be able to quadruple production of its cell therapy cancer treatments by 2026 due to improvements in the U.S. biotech's manufacturing processes, an... |
MedScape
15 March at 05.07 AM
Customized Radiation of Uterus May Not Compromise OutcomesResearchers found that patients with locally advanced cervical cancer who received less than whole uterus irradiation had low local recurrence rates and fewer side effects. |
MedScape
14 March at 11.24 PM
Look Beyond BMI: Metabolic Factors' Link to Cancer ExplainedResearchers delve deeper into metabolic syndrome trajectories finding that adults with persistent and worsening metabolic syndrome over time are at increased risk for any type of cancer. |
MedScape
14 March at 06.42 PM
FDA Approves New Esophageal Cancer DrugThe checkpoint inhibitor is approved for second-line treatment of patients with esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-L1 inhibitor. |
MedScape
14 March at 06.57 AM
Combining Drugs and Radiation in Breast Cancer: What's Safe?There are surprisingly little data on how to safely combine new targeted treatments for breast cancer alongside radiotherapy. Experts weigh in on what we know. |
MedScape
13 March at 11.54 PM
No Benefit to Adding Chemotherapy in Older Adults With NSCLCAdding chemotherapy to immunotherapy increased the adverse event burden without improving survival outcomes compared with immunotherapy alone in older adults with NSCLC. |
MedScape
13 March at 05.22 AM
Return to Direct Supervision in RT: Needed or 'Babysitting'?ASTRO has raised concerns over making virtual supervision of radiation oncology services a permanent fixture, pushing instead for a return to in-person only. But some oncologists oppose the move. |
MedScape
13 March at 02.57 AM
Consider These Factors in a Radiation Oncology PositionBefore accepting a position at an academic radiation oncology practice, a prospective employee should evaluate three main features of the job — compensation, daily duties, and location. |
MedScape
12 March at 09.11 AM
New Data: How Early Colon Cancer Cells Evade Immune SystemA new study reveals how early colorectal cancer cells may hide from the immune system, building on growing and crucial research on cancer immune evasion. |
MedScape
12 March at 04.48 AM
After SABR, 100% Local Control at 1 Year in Kidney CancerAmong patients with primary RCC who did not undergo surgery, SABR led to no local treatment failures at 1 year, new phase 2 data showed. |
MedScape
11 March at 02.07 PM
FTC, 10 US States Sue 'sham' Women's Cancer CharityThe Federal Trade Commission and 10 U.S. states on Monday sued what they called a "sham" charity that raised $18.25 million to help women fight cancer, but spent just... |
MedScape
11 March at 06.43 AM
TIL for Melanoma: What Are the Costs and Challenges?A new FDA-approved treatment for melanoma has hit the market with a high price, and clinicians are working with insurers to determine out-of-pocket costs for patients. |
MedScape
11 March at 06.21 AM
FDA Committee Gives New Cancer Surgery Tech a Positive VoteAlthough most of the FDA's Medical Imaging Drugs Advisory Committee supported LUMISIGHT (pegulicianine), which aims to detect residual cancer during lumpectomy, some cite safety concerns. |
MedScape
11 March at 05.20 AM
Drug Discount May Boost Adherence to Prostate Cancer TherapyThe 340B drug discount program was not associated with oral specialty drug use in advanced prostate cancer but was linked to better adherence to medication in more vulnerable patients, in a retrospective study. |
MedScape
11 March at 05.02 AM
MRI Screen Cuts Breast Cancer Mortality Risk in BRCA1+ WomenA new study suggested that MRI screening reduces the likelihood of breast cancer mortality in women with BRCA1 sequence variations by 80%. |
MedScape
08 March at 04.52 AM
A Case for Radiation Enhancement in Head and Neck CancerTwo new studies support a growing role for approaches that boost the effect of radiation in head and neck cancer. |
MedScape
08 March at 04.26 AM
Nivolumab Wins First-Line Indication in Metastatic UCThe FDA approved nivolumab alongside cisplatin and gemcitabine in the frontline for adults with unresectable or metastatic disease. |
MedScape
08 March at 01.46 AM
Zanubrutinib Label Expands to Include RR Follicular LymphomaThe Bruton's kinase inhibitors new follicular lymphoma indication is for combination use with obinutuzumab. |
MedScape
08 March at 01.23 AM
Does Exercise Reduce Cancer Risk? It's Just Not That SimpleAlthough guidelines tout the benefits of exercise for lowering cancer risk, the research on exercise and cancer risk paints a much more complex picture. |
MedScape
07 March at 06.41 AM
GSK's Blood Cancer Drug Meets Main Goal in Late-stage Trial; Analysts Tout ComebackGSK said on Thursday a study showed its experimental drug Blenrep helped extend survival in patients with a type of blood cancer without symptoms worsening, marking a... |
MedScape
07 March at 02.56 AM
FDA Okays Pfizer Antibody-Drug Conjugate for Pediatric ALLA complete remission rate of 42% led to the approval of inotuzumab ozogamicin for children. |
MedScape
06 March at 02.37 PM
Change Healthcare Cyberattack: 'Unsustainable' for OncologyChange Healthcare is focused on restoring its systems and minimizing disruptions to oncology practices after a cyberattack that occurred over 2 weeks ago. |
MedScape
06 March at 07.37 AM
Cancer-causing Chemical Found in Clinique, Clearasil Acne Treatments, U.S. Lab ReportsHigh levels of cancer-causing chemical benzene were detected in some acne treatments from brands including Estee Lauder's Clinique, Target's Up & Up and Reckitt... |
MedScape
06 March at 07.22 AM
Is Primary Tumor Resection Beneficial in Stage IV CRC?Primary tumor resection before chemotherapy does not prolong survival in patients with CRC and unresectable metastases, combined results from two trials indicate. |
MedScape
05 March at 03.29 AM
Can Changes to Chemo Improve Tolerability in Older Patients?Reducing treatment doses and altering treatment schedules can help reduce adverse events and improve tolerability in older patients with advanced cancer, a new study suggested. |
MedScape
05 March at 03.14 AM
'Less Is More' in MyelomaDr. Mohyuddin discusses "less is more" clinical trials that challenge conventional practices and have shown improved outcomes with lower drug dosages. |
MedScape
05 March at 02.27 AM
Oophorectomy Saves Lives in Women With BRCA1/2 MutationsIn women with BRCA1/2 pathogenic variants, preventive bilateral oophorectomy was associated with a 68% lower risk for death from any cause, a large cohort study found. |
MedScape
04 March at 05.22 AM
FDA Approves Amivantamab First-line Indication for NSCLCAmivantamab plus carboplatin and pemetrexed is now available for first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. |
MedScape
04 March at 05.21 AM
Fine Particulate Matter Affects EGFR-Mutated Lung CancersData suggest that patients with lung cancer who live in polluted areas have an additional 50% risk of carrying an oncogenic EGFR mutation. |
MedScape
04 March at 02.36 AM
Outside the Guidelines: Denosumab Overuse in Prostate CancerMany men with castration-sensitive prostate cancer receive the bone-modifying agent to prevent skeletal-related events, but that practice is not recommended and costs Medicare millions annually. |
MedScape
04 March at 12.45 AM
How Often Should Patients Receive Imaging After Spine SBRT?A new study suggested a tailored MRI approach based on patients' progression risk after stereotactic body radiotherapy for spinal metastases. |
MedScape
01 March at 05.01 AM
New Tool Gauges Post–CAR T Relapse Risk in Multiple MyelomaA simple prediction model developed with US and European cohorts effectively predicted relapse risk in multiple myeloma patients post anti-BCMA CAR-T therapy. |
MedScape
01 March at 01.24 AM
What Do Oncology Patients Think of Electronic Monitoring?A survey indicates that patients are open to electronic monitoring systems, but the latter require dedicated personnel to implement. |
MedScape
01 March at 12.26 AM
Mental Health Issues Tied to Worse Cancer Surgery OutcomesCancer patients with behavioral health disorders are less likely to have surgery and face worse outcomes when they do, according to a new study. |
MedScape
29 February at 09.19 AM
Many European Cancer Drugs Offer No Added BenefitTwo fifths of oncology drugs approved by the EMA over the past 25 years don't offer an added benefit, while their costs may be burdening health systems. |
MedScape
29 February at 06.48 AM
'There's Nothing Left to Try:' Oncologists on Managing GriefFive oncologists explored the challenges of caring for patients with cancer and how they deal with their complex feelings when a patient dies. |
MedScape
29 February at 02.40 AM
Digital Support Offers Relief for Cancer Caregivers' StressA customized psychoeducational intervention delivered through a mobile app to caregivers can reduce their anxiety and depression levels. |
MedScape
28 February at 10.42 PM
AML: Genetic Testing Unlocks HopeAML is a deadly form of blood cancer, but advancements in treatment options have improved survival rates, particularly for children. |
MedScape
28 February at 06.04 AM
New Trials in Leukemia/Lymphoma: Could Your Patient Benefit?Perhaps one of your patients would benefit from enrolling in a new clinical trial in leukemia or lymphoma? |
MedScape
27 February at 03.22 AM
Doxorubicin Ups Breast Cancer Risk in Hodgkin LymphomaThe findings may have implications for breast cancer surveillance among survivors of Hodgkin lymphoma. |
MedScape
26 February at 04.19 AM
Lung Cancer Survival Worse Among Canadian Inuit in QuebecA new study showed shorter survival among Inuit patients with lung cancer who were treated at McGill University, suggesting disparities in health services. |
MedScape
26 February at 01.21 AM
Managing Asparaginase Toxicity in ALLAsparaginase remains a mainstay of ALL treatment despite challenging side effects, with clinicians continuously adjusting therapy and developing new strategies to mitigate toxicity. |
MedScape
25 February at 11.09 PM
'Eating As Treatment' Linked to Improved Survival in HNCAn oncology dietician-led intervention improved nutritional status and significantly reduced 5-year mortality in patients with head and neck cancer undergoing radiotherapy. |
MedScape
23 February at 12.52 PM
European Approval for Lung and Skin Cancer DrugsThe European Medicines Agency granted marketing authorization for tislelizumab and retifanlimab for the treatment of non–small cell lung cancer and Merkel cell carcinoma, respectively. |
MedScape
23 February at 11.51 AM
EMA Approves Two Therapies for Rare Genetic DiseasesTreatments for amyotrophic lateral sclerosis and paroxysmal nocturnal hemoglobinuria have been given marketing authorization by the European Medicines Agency. |
MedScape
23 February at 09.43 AM
Democrats Press Pfizer on Chemotherapy Drug ShortagesDemocratic legislators on the House Committee on Oversight and Reform have written a letter to Pfizer, requesting information on how the company is addressing shortages of chemotherapy drugs. |
MedScape
23 February at 09.20 AM
Universal Early Cancer Detection: How Close Are We?Results of a major NHS pilot trial of a multicancer early detection test are due later this year. How much might such tests change medical practice? |
MedScape
23 February at 06.35 AM
HPV and Tobacco: Dangerous LesionsSmoking increases the risk for HPV infection by impairing immunity and reducing antibody titers, according to a gynecologist. |
MedScape
23 February at 05.57 AM
Communicating Bad News to PatientsThe manner in which bad news is communicated plays a significant role in the psychological burden on the patient. |
MedScape
23 February at 03.24 AM
Are Food Emulsifiers Associated With Increased Cancer Risk?The apparently increased risk for cancer associated with emulsifiers could translate into a significant number of preventable cancers at the population level. |
MedScape
23 February at 02.54 AM
Lung Cancer Radiation May Up AF RiskDuring radiotherapy for non–small cell lung cancer, an incidental dose of radiation to the pulmonary veins may trigger atrial fibrillation, a study has found. |
MedScape
23 February at 01.36 AM
Are AI Tools the Future of Mammography Screening?Early signs show AI in breast cancer screenings may enhance diagnosis, but questions persist on optimal integration and timely deployment. |
MedScape
22 February at 04.57 AM
Intellectual Disabilities Linked With Worse Cancer SurvivalPeople with intellectual or developmental disabilities may be 2.57 times more likely to die of colorectal cancer than those without these disabilities. |
MedScape
22 February at 04.53 AM
Osimertinib Plus Chemo Approved for EGFR-mutated NSCLCWith the new approval, patients now have the option of combination treatment or osimertinib monotherapy. |
MedScape
22 February at 12.35 AM
Perceived vs Actual Cognitive Impairment in Prostate CancerFollowing hormone therapy, patients with prostate cancer may perceive an increase in cognitive issues, despite tests showing no objective decline, a recent meta-analysis found. |
MedScape
21 February at 06.47 AM
Is MRI Screening Unnecessarily High in Prostate Cancer?New research suggests that review of current prostate cancer screening guidelines may be needed, as MRI frequently fails to detect cancer-indicative lesions, even in men with elevated PSA levels. |
MedScape
21 February at 03.26 AM
This Could Be a Strong Weapon for Cancer Pain (or Any Pain)New study on exercise and cancer-related pain adds to mounting evidence that physical activity can help manage pain for a range of conditions. |
MedScape
20 February at 01.56 AM
Focal Therapy for Prostate Cancer: Is It Being Oversold?Despite growing enthusiasm for this minimally invasive option for some men with prostate cancer, focal therapy is still not FDA-approved for prostate cancer and comes with high out-of-pocket costs. |
MedScape
19 February at 05.46 AM
Transcatheter Arterial Chemoembolization for Rectal Tumors?Chinese investigators have applied a technique long used for liver metastases to rectal cancer, with promising results. |
MedScape
16 February at 06.29 PM
FDA Approves First Cellular Therapy for Metastatic MelanomaLifileucel is the first cellular therapy to be approved to treat patients with unresectable or metastatic melanoma. |
MedScape
16 February at 05.05 AM
Should CRC Surveillance Extend Beyond 5 Years Post Surgery?The incidence of late recurrence and metachronous CRC remain low and have decreased over time, limiting the benefit of prolonged CRC-specific surveillance. |
MedScape
16 February at 05.05 AM
Should CRC Surveillance Extend Beyond 5 Years Post-Surgery?The incidence of late recurrence and metachronous CRC remain low and have decreased over time, limiting the benefit of prolonged CRC-specific surveillance. |
MedScape
16 February at 03.12 AM
Hyperbaric Oxygen: Effective Against Cancer Radiation Harm?Limited evidence and a significant time burden stand in the way of hyperbaric oxygen therapy becoming a more routine treatment for chronic radiation side effects in breast cancer. |
MedScape
15 February at 06.44 PM
Gilead Sciences Pauses Enrollment for Cancer Treatment in Solid Tumor TrialsGilead Sciences said on Thursday enrollments to test its cancer drug, magrolimab, on solid tumors had been paused globally, a week after the U.S. regulator put some studies... |
MedScape
15 February at 08.50 AM
New Trials in Gyn Cancers: Could Your Patient Benefit?Perhaps one of your patients could benefit from enrolling in a clinical trial looking for patients with gynecologic cancers. |
MedScape
15 February at 12.06 AM
CAR T Cell: Do Benefits Still Outweigh Risks?Despite concerns about the development of secondary T-cell malignancies due to CAR T-cell immunotherapy, experts still believed that the benefits outweigh the risks. |
MedScape
14 February at 04.48 AM
Cancer Surgery Tied to Increased Venous Thromboembolism RiskA new study suggested that the risk for venous thromboembolism remains significant for 1 year after surgery for most cancers. |
MedScape
14 February at 03.54 AM
Frontline Irinotecan Liposome OKed in Mets Pancreatic CancerThe approval was based on improved overall and PFS with irinotecan liposome alongside oxaliplatin, fluorouracil, and leucovorin vs gemcitabine plus nab-paclitaxel. |
MedScape
13 February at 05.44 AM
Routine Prophylactic Cranial Irradiation for SCLC QuestionedInvestigators found no significant survival benefit after prophylactic cranial irradiation in patients with SCLC who did not have preexisting brain metastases. |
MedScape
13 February at 02.54 AM
Do Multivitamin Supplements Lower Mortality Risk in CRC?A new study suggested that the use of multivitamin supplements at moderate doses may reduce the risk for cancer-related mortality in patients with CRC, but higher doses could have the opposite effect. |
MedScape
12 February at 06.12 AM
Add-On Fruquintinib Delays Progression in Gastric CancerFruquintinib plus paclitaxel improves cancer progression-free, but not overall survival, in patients with gastric/gastroesophageal cancer who have progressed on frontline chemotherapy. |
MedScape
12 February at 03.00 AM
Which Patients Benefit From Endocrine Therapy Beyond 5 Yrs?Japanese investigators identified a group of patients with breast cancer who demonstrated improved long-term outcomes on endocrine therapy beyond the usual 5 years. |
MedScape
12 February at 03.00 AM
Which Patients Benefit From Endocrine Therapy Past 5 Years?Japanese investigators identified a group of patients with breast cancer who demonstrated improved long-term outcomes on endocrine therapy beyond the usual 5 years. |
MedScape
09 February at 12.02 AM
Belantamab Mafodotin Tops Daratumumab in Multiple MyelomaThe phase 3 study findings supported belantamab mafodotin as a potential new standard of care in the second line or later among patients with released/refractory multiple myeloma. |
MedScape
08 February at 05.49 AM
Is Consolidation Osimertinib Superior in EGFR-Mutated NSCLC?A retrospective study showed consolidated osimertinib after chemoradiation prolonged progression-free survival in patients with EGFR-mutated, stage III NSCLC compared with durvalumab or observation. |
MedScape
08 February at 02.25 AM
Screening and Treatment Reduce Breast Cancer MortalitySimulation models indicate that breast cancer screening and treatment were associated with a 58% reduction in mortality, based on data collected between 1975 and 2019. |
MedScape
08 February at 02.09 AM
Immune-Related AEs Predict Outcomes in Advanced GU CancersPatients with advanced GU cancers who had immune-related AEs from immunotherapy had better overall survival — a phenomenon also reported for other cancer types. |
MedScape
07 February at 06.37 AM
Regrowth Predicts Metastasis in Rectal Cancer Watch and WaitA large retrospective study addressed the risk of opting for "watch and wait" in rectal cancer. |
MedScape
07 February at 04.01 AM
Robotic Mastectomy Is Feasible, But Is it Safe?One expert asks whether there is sufficient information about the oncologic safety of robotic mastectomy. |
MedScape
06 February at 06.46 AM
SBRT Safe, Effective for Patients With Nonspine Bone MetsStereotactic body radiation for nonspine bone metastases is associated with a low rate of local failures, fractures, and acute toxicity, according to a large meta-analytic review. |
MedScape
06 February at 05.14 AM
Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCCA new study showed improved progression-free survival when systemic therapy is added to TACE for HCC. Overall survival outcomes are pending. |
MedScape
06 February at 04.28 AM
Does Eliminating Alcohol Intake Lower Cancer Risk?When it comes to the link, a new report from WHO revealed limited or inadequate evidence to suggest consuming less alcohol or stopping altogether reduced the risk for most cancers. |
MedScape
05 February at 09.39 AM
Adding Apalutamide Boosts PSA Control in Prostate CancerAdding apalutamide to androgen deprivation therapy (ADT) prolongs prostate-specific antigen progression-free survival in patients with biochemically recurrent prostate cancer. |
MedScape
05 February at 07.28 AM
SBRT Shows Promise in Nonspinal Bone MetsDose-escalation through stereotactic body radiation therapy (SBRT) provides durable local control and pain responses that exceed historical outcomes with conventional radiotherapy. |
MedScape
02 February at 12.50 AM
Team IDs Key Factors for Synthetic Control Arm in Mets CRCResearchers identified a handful of prognostic factors to create a synthetic control arm, which can ultimately replace placebo control arms in future trials of salvage-line metastatic CRC. |
MedScape
01 February at 01.59 PM
WHO: Global Cancer Burden Rising Amid Striking Inequitiesa figure expected to increase 77% to 35 million by 2050, with poorer countries bearing the brunt, according to new data. |
MedScape
01 February at 01.59 PM
Global Cancer Burden Rising Amid Striking InequitiesGlobally, an estimated 20 million people developed cancer in 2022 – a figure expected to increase 77% to 35 million by 2050, with poorer countries bearing the brunt, according to new data. |
MedScape
01 February at 10.43 AM
Study Reveals Disparities in CRC Biomarker Testing TrendsTesting trends are consistent with guideline recommendations and FDA approvals, but demographic disparities exist. |
MedScape
01 February at 07.04 AM
Top Causes of Early Noncancer Deaths in Advanced GU CancersSepsis was the leading reason for early noncancer deaths in patients with metastatic bladder, kidney, or prostate cancer, a recent analysis found. |
MedScape
01 February at 07.00 AM
'Breakthrough': Adjuvant Pembro Ups Survival in Renal CancerKEYNOTE-564 is the first trial to demonstrate an overall survival benefit with adjuvant immunotherapy in patients with clear cell renal cell carcinoma. |
MedScape
01 February at 05.21 AM
Small PFS Gain in Metastatic Prostate Cancer With TKI, ICIMen with metastatic castration-resistant prostate cancer had a slight but significant improvement in progression-free survival with a TKI plus immunotherapy vs hormonal therapy. |
MedScape
01 February at 01.00 AM
Olaparib Combo Improves PFS in Metastatic Prostate CancerFrontline olaparib plus abiraterone/prednisone combo improves survival in patients with metastatic castration-resistant prostate cancer. |
MedScape
01 February at 01.00 AM
Olaparib combo improves PFS in metastatic prostate cancerFrontline olaparib plus abiraterone/prednisone combo improves survival in patients with metastatic castration-resistant prostate cancer. |
MedScape
30 January at 01.54 PM
Toxicity Linked to Longer Survival in Patients With NSCLCA new cohort study shows that some immune-related adverse events are linked to longer survival in patients with NSCLC treated with immunotherapy. |
MedScape
30 January at 08.41 AM
More Side Effects With Local Therapies for Prostate CancerLocal therapies for advanced prostate cancer were associated with significantly more gastrointestinal and sexual issues in subsequent years than systemic treatments. |
MedScape
30 January at 07.18 AM
ctDNA Clearance Predicts Relapse Risk in Urothelial CancerNew research shows that ctDNA clearance following neoadjuvant treatment of muscle-invasive urothelial cancer can help predict response to therapy and the risk for relapse. |
MedScape
30 January at 06.57 AM
Uncertainty Surrounds Sensitivity of ctDNA in CRCctDNA is a useful prognostic tool in CRC, but it's unclear whether it can guide the use of adjuvant chemotherapy. |
MedScape
30 January at 06.09 AM
Targeted Colorectal Cancer Combo Improves QoLPatients with metastatic colorectal cancer who have the KRAS G12C mutation demonstrated improved quality of life following sotorasib and panitumumab compared with standard therapy. |
MedScape
30 January at 03.22 AM
AMBASSADOR: Adjuvant Pembro Boosts DFS in Urothelial CancerInterim findings from the ongoing AMBASSADOR trial revealed a significant DFS benefit with adjuvant pembrolizumab but no overall survival benefit at this point. |
MedScape
29 January at 03.21 AM
New Guidelines: Start PSA Screening Earlier in Black MenStarting PSA screening in Black men earlier would reduce prostate cancer deaths by about 30%. |
MedScape
29 January at 12.49 AM
Chemo-Free Maintenance Strategies May Boost Survival in TNBCAdapting chemo-free maintenance strategies in TNBC could offer effective disease control while improving patients' quality of life. |
MedScape
29 January at 12.05 AM
Treatment Sequence May Impact Pancreatic Cancer SurvivalThe sequence of systemic therapies for advanced pancreatic ductal adenocarcinoma can affect overall patient survival, a new analysis suggests. |
MedScape
26 January at 04.59 PM
Higher-Dose RT Extends Survival in High-Risk Prostate CancerAdding higher dose radiation led to long-term ADT led to better progression-free, cancer-specific, and overall survival vs standard-dose radiation in men with high-risk prostate cancer. |
MedScape
26 January at 04.00 PM
Europe Approves Neutropenia and Schizophrenia TreatmentsRecommendations were also endorsed to institute measures to reduce risks from cold and flu medicines containing pseudoephedrine. |
MedScape
26 January at 08.49 AM
Young Myeloma Specialist Forges Ahead, Gives Back"Manni" Mohyuddin, MD, reflects on patient needs, compassionate care, medical education, and recent advances in treating multiple myeloma. |
MedScape
25 January at 07.54 AM
Study Validates Breast Recurrence Score Across Ethnic GroupsA recent study validated the predictive biomarker's effectiveness in guiding treatment decisions for diverse groups. |
MedScape
25 January at 05.42 AM
Data Support Upfront Radioligand Therapy in High-Grade NETsSome physicians commented, however, that they will reserve 177Lu-DOTATATE in the first line for the most aggressive cases. |
MedScape
25 January at 05.38 AM
Understanding Functional Outcomes in Prostate CancerNew study sheds light on quality-of-life effects related to disease severity and treatment choice in prostate cancer. |
MedScape
25 January at 04.44 AM
Europe Is Facing a Pancreatic Cancer EmergencyPeople living in Western Europe are more likely to develop pancreatic cancer than those living anywhere else in the world. |
MedScape
25 January at 02.13 AM
New Strategy Improves Early-Stage Ovarian Cancer DetectionA new screening approach demonstrated positive predictive value of 50% for ovarian cancer and 74% for any cancer, with most cancers detected in stages I and II. |
MedScape
25 January at 01.31 AM
Study Concludes Most Melanoma Overdiagnoses Are In SituQuantifying the frequency of overdiagnosis is important for policymakers, clinicians, and patients, the authors said. |
MedScape
24 January at 12.00 PM
Dana-Farber May Retract, Correct Over 30 Cancer PapersDana-Farber Cancer Institute is investigating allegations of data manipulation in dozens of research papers, some of which were authored by high-profile investigators. |
MedScape
24 January at 06.48 AM
Bladder Cancer: Is Active Surveillance the Way Forward?Active surveillance is safe and improves quality of life but requires careful patient selection and relevant follow-up, said one expert. |
MedScape
24 January at 06.05 AM
Will New Lung Cancer Screening Guidelines Save More Lives?Recent changes to lung cancer screening will expand the eligible population, but experts cautioned that long-standing barriers to screening may mean that screening rates remain low. |
MedScape
23 January at 08.45 AM
Immunotherapy Combo Wins Big on PFS in First-Line Mets CRCFirst-line nivolumab plus ipilimumab led to significantly better 2-year PFS in metastatic CRC than chemotherapy as well as pembrolizumab monotherapy. |
MedScape
23 January at 05.54 AM
Hepatic Infusion Pumps: New Enthusiasm for an Old TechnologyPatients with advanced, unresectable cholangiocarcinoma had significantly better survival outcomes after treatment with hepatic arterial chemotherapy infusion pumps vs standard therapy. |
MedScape
23 January at 02.09 AM
CT Poses Risk for Malignant Hematopathies Among ChildrenData suggest that risk increases even with low radiation doses. |
MedScape
22 January at 08.20 PM
US FDA Seeks 'boxed Warning' for CAR-T Cancer TherapiesThe U.S. health regulator said on Monday companies will be required to add a serious warning on the prescribing information for cancer therapies known as CAR-T, made by... |
MedScape
22 January at 05.25 AM
Cancer Deaths on Decline, But New Cases to Hit Record HighCRC is now the leading cause of cancer deaths in men under age 50 and the second in women under 50, according to the latest ACS annual report on cancer trends. |
MedScape
22 January at 02.30 AM
The Case for Biomarker Testing in Gastroesophageal CancerTo take advantage of the latest targeted therapies in gastroesophageal cancer, physicians needed to identify patients who will benefit, but biomarker testing in this population continued to lag. |
MedScape
22 January at 01.38 AM
Mirtazapine May Increase Energy Intake in NSCLC, AnorexiaThe proportion of patients with sarcopenia was low in the mirtazapine arm at 8 weeks. |
MedScape
19 January at 06.41 AM
Adaptive SABR Boost Shows Promise in Advanced NSCLCRadiation dose-escalation combined with stereotactic ablative radiotherapy may improve locoregional control in patients with NSCLC. |
MedScape
19 January at 05.26 AM
Immunotherapy Initiated Near Death in Metastatic CancerPatients with metastatic cancer are increasingly starting immunotherapy within a month prior to death, new data show. |
MedScape
19 January at 04.46 AM
How a Simple Urine Test Could Reveal Early-Stage Lung CancerMIT researchers have developed nanosensors you inhale that produce a signal that can be detected in urine. |
MedScape
19 January at 04.36 AM
Biomarker Testing Optimizes Therapy Choice in Advanced NSCLCPatients with advanced NSCLC who received optimal first-line treatment based on biomarker testing demonstrated better outcomes, new findings showed. |
MedScape
18 January at 08.36 AM
Oncologists Sound the Alarm About Rise of White BaggingMore states are barring the practice of white bagging, while oncology groups and insurance advocates continue to debate its impacts on costs. |
MedScape
17 January at 05.23 PM
CRISPR-Based Gene Therapy Earns Beta Thalassemia ApprovalExa-cel earned its second FDA approval. The one-time therapy, which has a list price of $2.2 million in the United States, should be available for patients early this year. |
MedScape
17 January at 06.03 AM
Coming Soon: The First mRNA Vaccine for Melanoma?Results of a phase 2b trial were favorable, and Moderna suggests that an mRNA vaccine for melanoma could be available in 2025. |
MedScape
17 January at 03.58 AM
Standard Therapy Beats Out Primary Surgery in Rectal CancerIn locally advanced rectal cancer, primary surgery followed by selective adjuvant chemoradiation was inferior to standard neoadjuvant preoperative chemoradiation followed by surgery. |
MedScape
16 January at 12.04 PM
Radiation Oncologists Fight for Payment Reform Amid CutsSince 2013, radiation oncologists have seen a 23% drop in Medicare payments for radiation therapy services. |
MedScape
16 January at 09.52 AM
FDA Approves Pembrolizumab for Stage 3/4a Cervical CancerThe new approval marks the 40th oncology indication for pembrolizumab across 19 cancer types, including two previous metastatic cervical cancer approvals. |
MedScape
15 January at 05.34 AM
Testosterone Replacement Therapy and Prostate Cancer RiskA large randomized controlled trial found that testosterone replacement therapy did not increase the risk for prostate cancer in middle-aged and older men with hypogonadism. |
MedScape
12 January at 05.04 AM
Is Axillary Surgery for Abemaciclib Candidacy Overused?Many women with HR–positive, HER2–negative breast cancer may be exposed to unnecessary axillary surgery, new data show. |
MedScape
11 January at 08.03 AM
Psilocybin Promising for Depression in Cancer PatientsPsilocybin-assisted group therapy with psychological support led to clinically meaningful reductions in depression symptoms in cancer patients with major depressive disorder. |
MedScape
10 January at 01.01 PM
FDA Rejects GI Cancer Drug Over Manufacturing IssuesThe manufacturer of the drug, zolbetuximab, says it is working closely with the FDA to resolve the issues. |
MedScape
10 January at 06.32 AM
Clinical Exams Fall Short in Second Breast Cancer DetectionA decade-long surveillance study shows clinical breast examinations are largely ineffective in detecting second cancers in women treated for ductal carcinoma in situ. |
MedScape
10 January at 01.22 AM
What Prompts a Post-Childhood 'Survival Cliff' in ALL?Experts explore why children with acute lymphoblastic leukemia fare well with current treatment options, while adolescents and younger adults still face high mortality rates. |
MedScape
09 January at 06.11 AM
Side Effects of Local Therapy for Prostate Cancer May LingerLocal treatment for advanced prostate cancer was associated with a higher burden of persistent treatment-related adverse effects than with nonlocal therapy alone. |
MedScape
09 January at 12.21 AM
First ALL Treatment Guidance for Young Patients in the Works: The American Society of Hematology is developing the first clinical practice guidelines for treating acute lymphocytic leukemia in adolescents and young adults. |
MedScape
08 January at 07.01 PM
US FDA Declines to Approve Astellas' Gastric Cancer DrugJapan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing... |
MedScape
08 January at 07.35 AM
Nodal Radiation May Make BC Axillary Dissection UnnecessarySome patients with breast cancer may be able to skip axillary lymph node dissection if they plan to have adjuvant nodal radiation. |
MedScape
08 January at 05.43 AM
Gastric Cancer Survival Differs by Race and EthnicityOverall, Asian and Hispanic patients demonstrated better survival than White and Black patients. |
MedScape
08 January at 05.00 AM
Some Breast Cancer Surgery Patients Travel Further For CareDecision-making can be based on media prestige. |
MedScape
05 January at 05.37 AM
Magnetic Seeds/Guidewires for Breast Cancer Localization?Paramagnetic seeds work as well as guidewires for breast tumor localization and are easier to use, but it's not yet clear whether the costs of the seeds outweigh the benefits. |
MedScape
04 January at 10.31 AM
'Left in the Dark': Prior Auth Erodes Trust, Costs MoreA surprising prior authorization requirement left an oncologist's patient in extreme pain over the weekend. |
MedScape
04 January at 06.16 AM
Prior Auth Tied to Delays, Discontinuation of Cancer MedsThe introduction of a new prior authorization requirement for an established oral anticancer regimen led to more treatment delays and discontinuations among Medicare beneficiaries. |
MedScape
03 January at 02.25 AM
Optimal Follow-up After Cervical Cancer SurgeryInstead of using a one-size-fits-all approach, monitoring for cancer recurrence after fertility-sparing cervical cancer surgery can be tailored based on HPV testing and cytology. |
MedScape
28 December at 03.00 PM
How Do Patients View Their Cancer Test Results?With electronic patient portals, patients see their test results sooner and more frequently before their clinician, a recent analysis found. |
MedScape
28 December at 01.43 PM
No Added Benefit From Chemo in This Breast Cancer SubtypeAdding chemotherapy to endocrine therapy for women with ER-positive, HER2-negative invasive lobular carcinoma does not improve survival outcomes. |
MedScape
28 December at 01.21 AM
Record-High Wait Lists for Cancer, Other Surgeries in QuebecThe passage of Bill 15, a wide-ranging healthcare reform proposal, could provide relief but not in the short term. |
MedScape
27 December at 09.59 AM
New Trials in Breast Cancer: Could Your Patient Benefit?Patients with breast cancer might be eligible to enroll in one of these clinical trials. |
MedScape
26 December at 06.14 AM
ICIs in Melanoma: Predicting Immune-related Adverse EventsMelanoma histopathology predicted which patients were most likely to develop immune-related adverse events while taking checkpoint inhibitors. |
MedScape
21 December at 02.09 AM
The Latest Findings on Major Breast Cancer TrialsHere's a roundup of the most recent data from five phase 3 trials presented at SABCS 2023. |
MedScape
21 December at 01.53 AM
Serum Hormones May Predict AI Benefit for BC PreventionMeasuring serum hormone concentrations in postmenopausal women at high risk for developing BC may help identify those most likely to benefit from preventive treatment with an aromatase inhibitor. |
MedScape
19 December at 05.53 PM
New Multiple Myeloma Staging Systems Outperform the StandardFindings from a large US cohort study show comparable accuracy, but better discrimination of patients across disease stages. |
MedScape
19 December at 02.39 PM
Infection Main Cause of Nonrelapse Death With CAR T TherapyInfections, cardiopulmonary disease, and second cancers were among the leading causes of nonrelapse deaths in patients receiving CAR T-cell therapy, both in clinical trials and clinical practice. |
MedScape
18 December at 03.29 PM
Sickle Cell CRISPR Therapy May Offer 'Functional Cure'Patients with severe sickle cell disease could soon be freed from vaso-occlusive crises after receiving an infusion of exa-cel, the first gene-editing therapy to use CRISPR technology. |
MedScape
18 December at 12.00 PM
FDA OKs Enfortumab Vedotin Plus Pembro for Urothelial CancerThe combination is the first approved alternative to first-line chemotherapy. |
MedScape
18 December at 12.00 PM
EU Conditional Approval: Gene Editor to Treat Blood DiseasesThe single-dose therapy involves treating and editing patient stem cells ex vivo, then reinfusing them. |
MedScape
18 December at 07.12 AM
Checkpoint Therapeutics Slides After US FDA Declines Cancer Therapy ApprovalCheckpoint Therapeutics said on Monday the U.S. Food and Drug Administration had declined to approve its experimental therapy to treat a form of skin cancer following an... |
MedScape
15 December at 02.34 PM
Pregnancy Safe After BRCA-Mutated Breast CancerAlthough pregnancy after breast cancer is considered safe in general, little data exist for BRCA carriers. |
MedScape
15 December at 08.49 AM
Belzutifan Approved for Advanced Renal Cell CarcinomaThe FDA approval makes belzutifan the first agent specifically indicated for renal cell carcinoma that has progressed after checkpoint inhibition and a VEGF-TKI. |
MedScape
14 December at 05.12 PM
This Frontline Therapy Is Better in Multiple Myeloma: StudyA study directly comparing real-world outcomes suggests patients with transplant-ineligible multiple myeloma do better with frontline triple therapy with daratumumab vs bortezomib. |
MedScape
14 December at 02.57 PM
Survival-Toxicity Trade-off With T-DM1 in HER+ Breast CancerOlder patients with advanced HER2+ breast cancer do not experience a survival benefit with trastuzumab emtansine vs standard-of-care combination therapy, although toxicity is improved, a trial shows. |
MedScape
14 December at 12.00 PM
SCD Mortality Rates Improved for Black Patients in 2010sThe average age of death for Black US patients with sickle cell disease rose from 39 years in 1999-2009 to 43 years in 2010-2020, reflecting improvements in treatment. |
MedScape
14 December at 10.31 AM
Antiparasitic Wins FDA Approval for High-Risk NeuroblastomaThe FDA approved eflornithine to treat this rare cancer in adult and pediatric patients. The drug has also been approved to reduce excessive facial hair growth and to treat sleeping sickness. |
MedScape
13 December at 04.06 PM
Less Is More for Axillary Surgery in Early Breast CancerWomen with early breast cancer can safely undergo less extensive axillary surgery because it has no impact on recurrence or mortality rates but reduces the risk for lymphedema, a meta-analysis shows. |
MedScape
13 December at 03.44 PM
No Benefit to Salvage Transplant in R/R Multiple MyelomaLong-term follow-up shows no progression-free or overall survival advantage among patients who received salvage transplant vs continuous lenalidomide plus dexamethasone. |
MedScape
13 December at 02.46 PM
'Baby Tam' Effective, Tolerable for Breast Cancer PreventionLower-dose tamoxifen aims to reduce those side effects, but there remains some uncertainty about the minimum dose required to maintain efficacy. |
MedScape
13 December at 02.00 PM
Few With Inflammatory Breast Cancer Get Guideline-Based CareA US study finds a surprisingly low rate of guideline-concordant care in women with inflammatory breast cancer. |
MedScape
13 December at 01.54 PM
Sickle Cell: Good Outcomes for Haploidentical TransplantsIt is much easier to find eligible haploidentical donors — half-matched or partially matched — than eligible hematopoietic donors. |
MedScape
13 December at 01.35 PM
Mantle Cell Lymphoma: Drug Combo Improves PFS'In the countries where ibrutinib is indicated, this combination should be a new standard therapy for relapsed/refractory mantle cell lymphoma.' |
MedScape
13 December at 01.03 PM
Europe Approves Avapritinib for Rare Mast Cell DiseaseThe drug targets a mast cell mutation that gives rise to indolent systemic mastocytosis, a rare and debilitating blood disorder. |
MedScape
12 December at 04.22 PM
Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity'This [research] builds on our experience that four-drug combinations with a monoclonal antibody, proteasome inhibitor, immunomodulatory drug, and steroids are superior to three-drug combinations.' |
MedScape
12 December at 04.01 PM
The Unknowns of Taxanes for Breast Cancer During PregnancyTaxane exposure during pregnancy appears to be safe for mothers and offspring, according to a new retrospective cohort analysis. |
MedScape
12 December at 02.44 PM
MRD Status Predicts Transplant Benefit in NPM1-Mutated AMLMRD-positive patients in first complete remission after induction therapy had a survival benefit after transplant; however, that benefit did not extend to MRD-negative patients after transplant. |
MedScape
12 December at 02.08 PM
Women 50+ May Safely Reduce Mammogram Frequency Post-SurgeryWomen aged 50 and older who have undergone curative treatment for breast cancer and remain cancer free after 3 years may safely deescalate mammogram surveillance. |
MedScape
12 December at 02.05 PM
Measurable Residual Disease-Guided Therapy Promising in CLLThe ibrutinib-venetoclax combination was particularly effective in patients with chronic lymphocytic leukemia with high-risk features such as IGHV unmutated disease or chromosomal abnormalities. |
MedScape
12 December at 12.44 PM
Relapsed DLBCL: Complete Interim Response, SCT Beats CAR T'In patients with relapsed DLBCL in a complete remission, treatment with auto-HCT is associated with a lower rate of relapse/progression, and a longer progression-free survival [versus CAR T therapy].' |
MedScape
11 December at 06.00 PM
Distinct Toxicity Profiles for Anti-BCMA Myeloma TherapiesCAR T cells directed against the B-cell maturation antigen (BCMA) are linked to systemic and neurological side effects, while the antibody teclistamab is associated with increased infection risk. |
MedScape
11 December at 05.02 PM
Oncotype Score Helps Avoid Unnecessary Radiation in DCISUsing a gene test to guide radiation decisions may reduce overtreatment in ductal carcinoma in situ. |
MedScape
11 December at 04.57 PM
Endometrial Cancer Therapy Combo Fails 1L Treatment TrialMerck said on Friday a combination therapy being developed with partner Eisai failed a late-stage trial testing it as a first-line treatment for a type of cancer in the uterus lining. |
MedScape
11 December at 01.16 PM
Living in a Food Swamp Tied to High Breast Cancer MortalityNew research shows higher postmenopausal breast cancer mortality in communities with easier access to unhealthy fast food. |
MedScape
10 December at 12.00 PM
Sickle Cell Gene Therapy 'Truly Transformative'Patients who received lovo-cel had durable remissions and reductions in vaso-occlusive events, pain crises, and hospitalizations in the longest running gene therapy trial for sickle cell disease. |
MedScape
10 December at 12.00 PM
CAR T-Cell Therapy: Cure for Systemic Autoimmune Diseases?CD19-directed CAR T-cell therapy led to persistent complete remission in 15 patients with three distinct autoantibody-dependent autoimmune diseases. |
MedScape
09 December at 12.00 PM
In Real World, Patients With Myeloma Have Worse OutcomesA new analysis found that patients with multiple myeloma receiving standard therapies have much worse outcomes compared with those treated in clinical trials. |
MedScape
09 December at 12.00 PM
This Test May Guide AML Therapy for Black Pediatric PatientsA new analysis suggests that a polygenic score can help determine the best drug regimens for young Black patients with AML who often face worse outcomes than White patients. |
MedScape
08 December at 04.49 PM
Can Younger Postmenopausal Women With BC Skip Radiation?Women aged 65-70 years old are often offered the option of skipping radiation after lumpectomy for hormone receptor–positive early-stage breast cancer and moving straight to endocrine therapy. |
MedScape
08 December at 04.13 PM
Merck's Lung Cancer Drug Combo Fails TrialMerck said on Thursday a combination treatment testing a new type of immunotherapy failed to significantly slow disease progression in lung cancer patients who did not respond to previous treatments. |
MedScape
08 December at 03.29 PM
Trop-2 Drug Conjugate May Trump Chemo in HR+, HER2- BRCAIf approved, the ADC would join sacituzumab govitecan (Trodelvy, Gilead) as agents that target trophoblast cell-surface antigen-2 (Trop-2), which is universally expressed in breast cancer. |
MedScape
08 December at 03.09 PM
Patients With HR-Positive Breast Cancer Can Safely Use ARTNew data from the POSITIVE trial show the efficacy and short-term safety of fertility preservation and assisted reproductive technology (ART) for young women with HR-positive breast cancer. |
MedScape
08 December at 01.06 PM
FDA OKs Two Gene-Editing Therapies for Sickle Cell DiseaseThe approval for the two gene-editing treatments, called exa-cel and lovo-cel, could help thousands with the blood disorder. |
MedScape
07 December at 04.57 PM
HER2+ Combo Shows Promise in Breast Cancer Brain MetsIn previously treated patients with locally advanced unresectable or metastatic HER2-positive breast cancer, tucatinib and trastuzumab emtansine improved progression-free survival vs T-DM1 alone. |
MedScape
07 December at 03.27 PM
Sleep Problems Exact High Toll in Women With Breast CancerIt's important to ask about sleep and provide targeted interventions to improve sleep and quality of life in women with breast cancer, researchers say. |
MedScape
07 December at 12.00 PM
When to Skip Regional Nodal Radiation in Breast CancerWhen neoadjuvant chemotherapy turns positive lymph nodes negative, 5-year survival outcomes are the same whether patients have regional nodal irradiation or not. |
MedScape
07 December at 06.30 AM
Compelling Case for Skipping RT in Some Early Breast CancersResults of the PROSPECT study have defined a role for preoperative MRI in identifying a subgroup of women with early breast cancer who could consider skipping radiation therapy. |
MedScape
06 December at 02.36 PM
FDA OKs Iptacopan to Treat Paroxysmal Nocturnal HemoglobinuriaThis marks the first oral monotherapy approved for the rare blood disorder. |
MedScape
06 December at 02.07 PM
What Will Help Ease the Financial Toll of Breast Cancer?Programs that offer financial assistance and transportation as well as grants that help cover expenses are among the key strategies that can help reduce the financial stress of breast cancer care. |
MedScape
06 December at 09.29 AM
J&J Says It Has Settled Some Talc ClaimsJohnson & Johnson's worldwide vice president for litigation said on Tuesday that the company has recently reached settlements with several law firms over their clients' claims that J&J talc products caused cancer. |
MedScape
06 December at 09.26 AM
Replimune Skin Cancer Therapy Fails Midstage StudyReplimune Group said on Tuesday its experimental combination therapy to treat a common form of skin cancer failed to significantly remove or reduce cancerous lesions in a midstage study. |
MedScape
05 December at 06.00 PM
Cancer Prognosis Tied to Short-Term Suicide RiskPoorer prognosis after a cancer diagnosis was strongly associated with a higher suicide risk within 6 months of diagnosis, according to an analysis of US registry data. |
MedScape
05 December at 05.50 PM
Even With Insurance, Cancer OOP Costs Can Be PunishingCommercial health insurance does not necessarily protect cancer patients from potentially devastating out-of-pocket costs. |
MedScape
05 December at 02.28 PM
Addressing Chemo-Related Amenorrhea in Early BRCAPersistent chemotherapy-related amenorrhea (CRA) after treatment for breast cancer was common and associated with worse long-term quality of life among premenopausal women. |
MedScape
05 December at 12.34 PM
Radioimmunotherapy Tops ASCT in R/R Follicular LymphomaA new trial from Italy challenges a decades-old assumption that autologous stem cell transplant is more effective than radioimmunotherapy for consolidation after follicular lymphoma relapse. |
MedScape
04 December at 05.58 PM
ASH 2023: Equity, Sickle Cell, and Real-Life OutcomesHealth equity, sickle cell disease, and the thoughtful use of artificial intelligence and social media are among the key themes to be presented at the annual meeting of the American Society of Hematology. |
MedScape
04 December at 03.14 PM
How the Microbiome Influences the Success of Cancer TherapyMicrobial diversity affects whether a tumor grows, leads to inflammation, develops immune escape mechanisms, or develops therapeutic resistance, said an internal medicine specialist. |
MedScape
04 December at 09.23 AM
FDA Approves Pirtobrutinib for Previously Treated CLL/SLLThe approval is the second this year for the reversible, highly selective kinase inhibitor following a January approval in mantle cell lymphoma. |
MedScape
01 December at 08.50 AM
SABCS 2023 Highlights Breast Cancer De-EscalationFrom humble beginnings in 1977, 10,000 people are expected to attend this year's breast cancer meeting in San Antonio. |
MedScape
30 November at 05.46 PM
ASCO Details How to Manage Ongoing Cancer Drug ShortageThe guidance also recommends counseling to help patients and providers who are struggling with 'psychological or moral distress' from ongoing shortages. |
MedScape
30 November at 03.04 PM
Time to Stop Routine Maintenance Therapy in Myeloma?Physicians may need to rethink maintenance with lenalidomide (Revlimid and generics) for multiple myeloma. |
MedScape
29 November at 01.04 PM
Avoid Anti-HER2 Cancer Therapies During PregnancyWomen with HER2-positive breast cancer who receive HER2-targeted therapies during pregnancy face a higher risk for severe adverse outcomes to their fetus or newborn, new research indicates. |
MedScape
29 November at 12.32 PM
MRIs, MRI-Guided Biopsies Detect Prostate Cancer AffordablyStandard biopsies sometimes fail to detect prostate cancer or produce false positives. MRI plus MRI-guided biopsies not only produce more accurate results but carry a fair price tag, researchers said. |
MedScape
29 November at 10.21 AM
SpringWorks' Noncancerous Tumor Drug to Cost $29,000 Per MonthSpringWorks Therapeutics' drug for treating adult patients with a type of rare noncancerous soft-tissue tumor will be sold in the US at a list price of $29,000 for a 30-day supply. |
MedScape
28 November at 04.47 PM
FDA Investigates Secondary Cancers From CAR T-Cell TherapiesThe FDA has determined that the risk for lymphoma and other T-cell cancers may apply to approved BCMA- and CD-19–directed CAR T-cell immunotherapies. |
MedScape
28 November at 02.41 PM
FDA OKs New Agent to Block Chemotherapy-Induced NeutropeniaThe new colony-stimulating factor from China proved comparable to pegfilgrastim (Neulasta) in clinical testing. |
MedScape
28 November at 02.41 PM
FDA OKs New Agent to Block Chemotherapy-Induced NeutropeniaThe new colony-stimulating factor from China proved comparable to pegfilgrastim (Neulasta) in clinical testing. |
MedScape
28 November at 10.37 AM
ASTRO Updates on Partial Breast Irradiation in Early CancerThe new guideline replaces 2017 guidance after new evidence from multiple large trials emerged, indicating comparable outcomes with partial and whole breast radiation. |
MedScape
28 November at 04.55 AM
Long-Term Organ Preservation in Rectal Cancer Is PossibleLong-term data from the OPRA trial show organ preservation at 5 years in about half of patients with stage II/III rectal adenocarcinoma who received total neoadjuvant therapy. |
MedScape
27 November at 06.14 PM
FDA Approves Nirogacestat for Desmoid TumorsThis is the first drug approved to treat desmoid tumors. |
MedScape
27 November at 09.12 AM
Grail Gets FDA OK for Study of Cancer Blood TestGrail announced a step that may help move the company closer to securing Medicare reimbursement for its Galleri multicancer blood test, sold in the US since 2021. |
MedScape
22 November at 09.41 AM
White House Appoints New NCI DirectorAfter years of working with the National Cancer Institute, W. Kimryn Rathmell, MD, PhD, gets the call to run the institute. |
MedScape
21 November at 10.48 AM
How Should We Screen Transgender Patients for Cancer?The risk of cancer is not eliminated with gender transition, and the methods of screening should be adapted, say experts. |
MedScape
21 November at 10.46 AM
Redispensing Unused Cancer Meds Cuts Waste, Saves MoneyRedispensing unused oral anticancer medications has the potential to improve sustainability and affordability of cancer treatment. |
MedScape
21 November at 09.41 AM
New Trials in GI Cancers: Could Your Patient Benefit?Maybe one of your patients can join a new clinical trial in noncolorectal gastrointestinal cancer? |
MedScape
21 November at 09.38 AM
Choosing the Right Approach to Cancer and Menopause SymptomsHormone replacement therapy may be considered to lessen these symptoms, but only in certain conditions, said a gynecologist. |
MedScape
20 November at 01.01 PM
Bayer Recalls One Lot of Cancer Drug VitrakviBayer said on Friday it was voluntarily recalling one lot of its cancer drug Vitrakvi in the US due to the presence of microbial contamination that was observed during routine stability testing. |
MedScape
20 November at 12.31 PM
Surgery Is Falling Out of Favor in Rectal CancerWith organ preservation on the rise, investigators say practice guidelines need to catch up. |
MedScape
20 November at 10.37 AM
Risk for CRC Recurrence After Surgery Is FallingA marked reduction in colorectal cancer recurrence after surgery has led investigators to wonder whether some patients can skip intensive surveillance afterward. |
MedScape
17 November at 04.04 PM
FDA Panel Voices Concerns Over Two Lymphoma Rushed Approvals'The consensus of the advisory committee is that we have significant concerns about the very prolonged delay and getting these confirmatory studies underway.' |
MedScape
17 November at 03.26 PM
FDA Expands Enzalutamide Approval to Earlier Prostate CancerThe expanded approval makes enzalutamide the first and only approved androgen receptor signaling inhibitor in the nonmetastatic castration-sensitive prostate cancer setting. |
MedScape
17 November at 11.00 AM
Can a Mediterranean Diet Reduce Breast Cancer Recurrence?New research found that improving diet quality did not protect against breast cancer recurrence overall; however, a subset of women who made the greatest dietary changes did benefit. |
MedScape
17 November at 10.53 AM
Early Breast Cancer Detection From Breast MilkScientists in Spain have detected circulating tumor DNA in breast milk even before it appeared in blood. |
MedScape
17 November at 10.52 AM
FDA OKs First-Line Pembro With Chemo for Gastric/GEJ CancerAdding pembrolizumab to chemotherapy had significant benefits in patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma. |
MedScape
17 November at 09.11 AM
FDA OKs Capivasertib for Certain Advanced Breast CancersThe first-in-class AKT inhibitor administered with fulvestrant prolonged PFS vs fulvestrant alone in patients with PIK3CA/AKT1/PTEN-altered tumors. |
MedScape
16 November at 03.11 PM
ESMO 2023: Tarlatamab Shows Promise for Small Cell Lung Cancer"We are seeing some truly surprising response rates and progression-free survival data," says chairman of Unicancer and general director of the Léon Bérard Center in France. |
MedScape
16 November at 02.45 PM
FDA Approves Repotrectinib for ROS1-Positive NSCLCThe next-generation tyrosine kinase inhibitor provides a new treatment option for patients with this difficult-to-treat form of lung cancer. |
MedScape
16 November at 09.25 AM
Certain NSCLC Subgroups May Not Benefit From ImmunotherapyA comprehensive study exploring NSCLC subgroup responses to immunotherapy may help determine which patients are less likely to benefit from these agents. |
MedScape
15 November at 10.28 AM
Surveillance Imaging After Head, Neck Cancer Remission?With no apparent benefit for most, investigators say routine surveillance imaging in asymptomatic patients with head and neck cancer "should be discouraged." |
MedScape
15 November at 09.07 AM
Study Confirms Small Blood Cancer Risk From CT ScansThe increased risk of hematological malignancies from CT radiation exposure in children and young adults should be viewed in the context of the substantial benefit these scans offer, experts say. |
MedScape
15 November at 07.30 AM
Project Optimus Aims to Transform Early Cancer ResearchThe FDA has launched Project Optimus to dramatically overhaul how oncology therapies are developed in clinical trials, with investigational blood cancer drugs taking center stage in this effort. |
MedScape
14 November at 12.30 PM
Optimal Timing of Postop Radiosurgery for Brain MetastasesAdjuvant stereotactic radiosurgery for brain metastases delivered within 22 to 30 days is associated with lower rates of adverse effects and a low failure rate, new research suggests. |
MedScape
14 November at 10.41 AM
Production of Cancer Drug Cisplatin Resumed Amid ShortagesThe FDA said on Monday that Accord Healthcare has resumed manufacturing of commonly used cancer drug cisplatin against the backdrop of ongoing drug shortages in the United States. |
MedScape
14 November at 10.27 AM
False-Positive Mammography Results and Risk for Cancer DeathAfter a false-positive mammography result, women have a higher risk of developing and dying of breast cancer, but the risk varies by patient-specific characteristics. |
MedScape
13 November at 01.23 PM
Meta-Analysis Backs Nodal Radiation in Early Breast CancerInvestigators say their meta-analysis of 16 trials spanning six decades highlights the benefits patients and oncologists can expect from regional lymph node radiation for early breast cancer. |
MedScape
13 November at 11.18 AM
How Does Smoking Cause Cancer?'Stop-gain' mutations interfere with the function of tumor suppressors, making it easier for cancer to take hold. |
MedScape
10 November at 03.40 PM
Treating Cancer Survivors at Increased Cardiovascular RiskA cardio-oncology rehabilitation model for cancer survivors at high cardiovascular risk may lead to greater improvements in peak oxygen consumption in comparison with usual care. |
MedScape
10 November at 11.40 AM
TLS in Tumors May Predict Immunotherapy Benefit in NSCLCNew data indicate that tertiary lymphoid structures could predict which patients with advanced non-small cell lung cancer will benefit most from immunotherapy. |
MedScape
10 November at 09.03 AM
FDA Approves First Drug for Rare, Deadly Clotting DisorderAdzynma is the first treatment to become available for patients with congenital thrombotic thrombocytopenic purpura. |
MedScape
09 November at 03.44 PM
FDA Amends Pembrolizumab Indication in Gastric CancerThe revised indication is based on recent findings from a prespecified interim analysis showing little benefit in patients whose tumors do not express PD-L1. |
MedScape
09 November at 03.18 PM
T-Cell Cancers: CAR T Therapy to the Rescue?Scientists are seeing positive early results from treating relapsed/refractory T-cell blood cancers with un–gene-edited chimeric antigen receptor (CAR) T-cell therapy. |
MedScape
09 November at 03.00 PM
Catching a KillerMarcy Duncan hadn't fully healed from her surgery for stage I breast cancer. She expected to discuss radiation and other next treatment steps. But her doctor raised a more serious concern. |
MedScape
09 November at 02.09 PM
FDA Approves Fruquintinib for Metastatic Colorectal CancerThis marks the first approval for the oral anti-VEGFR tyrosine kinase inhibitor. |
MedScape
09 November at 02.05 PM
Tumor Debulking in Mets CRC Does Not Affect Quality of LifePatients with metastatic colorectal cancer can be reassured that their overall quality of life likely won't suffer if they opt for tumor debulking, a new study suggests. |
MedScape
09 November at 06.40 AM
Prior Authorizations Interfere With Cancer CarePrior authorization requirements delay or preclude recommended treatment in a substantial proportion of oncology patients. |
MedScape
09 November at 06.16 AM
T-DXd Benefits Persist for HER2-Low Breast CancerTrastuzumab deruxtecan (T-DXd) provided sustained clinically meaningful improvement versus physician’s choice of treatment (TPC) for patients with advanced breast cancer and low HER2 expression. |
MedScape
08 November at 12.06 PM
Model Helps Optimize Who Should Be Screened for CancerResearchers have identified biomarkers, alongside clinical risk factors, that may provide better cancer risk assessment and identify individuals who should be screened. |
MedScape
07 November at 04.39 PM
Low Vit D Linked to Paclitaxel-Induced Peripheral NeuropathyThe analysis, which evaluated patients with early-stage breast cancer, suggests that correcting vitamin D levels before treatment might help prevent peripheral neuropathy. |
MedScape
07 November at 04.02 PM
Benefits of Tebentafusp in Uveal Melanoma Last 3 YearsA new analysis suggests that the treatment's benefits for overall survival endures for at least 36 months. |
MedScape
07 November at 09.22 AM
Particulate Pollution Increases the Risk for Breast CancerUnlike previous research, a recent study examines exposure to fine particulate matter pollution at home and at the workplace. |
MedScape
07 November at 09.19 AM
Pervasive 'Forever Chemicals' Linked to Thyroid Cancer?A small study suggests that environmental PFAS exposure may raise the risk for thyroid cancer. But a biostatistician who reviewed the findings is not convinced. |
MedScape
06 November at 04.53 PM
Breaking Barriers to CRC for Black PatientsAccess to care for the highly preventable disease is thought to be behind why Black Americans are 20% more likely to receive a colorectal cancer diagnosis than any other racial or ethnic group. |
MedScape
06 November at 12.02 PM
Selpercatinib Extends PFS in First-line RET-Positive NSCLCA randomized trial found that selpercatinib improved PFS by more than two-fold, but overall survival data remain immature. |
MedScape
06 November at 10.31 AM
How Can We Improve Our Approach to Cancer-Related Fatigue?Cancer-related fatigue is one of the most underestimated and least researched side effects, said an oncology consultant who spoke at the European Society for Medical Oncology's 2023 Conference. |
MedScape
03 November at 01.37 PM
Q&A: Cancer Screening in Older PatientsMuch of the burden of cancer screening falls on primary care physicians. |
MedScape
03 November at 01.37 PM
Omitting Surgery May Be Safe in Early BC After pCRA small trial has helped to further identify women who can safely skip surgery after neoadjuvant therapy for early breast cancer. |
MedScape
03 November at 12.57 PM
Vaginal Estrogen Therapy Safe for Women With Breast CancerWomen with breast cancer can use vaginal estrogen tablets and creams without an increased risk for breast cancer–specific mortality, according to results from a recent UK-based study. |
MedScape
03 November at 10.22 AM
ACS Expands Lung Cancer Screening EligibilityThe American Cancer Society recently updated its screening guidelines for lung cancer. Here's what's new. |
MedScape
02 November at 01.41 PM
ADC With Radiotherapy for Brain Mets Ups Risk of NecrosisAn antibody-drug conjugate given concurrently with stereotactic radiotherapy to treat brain metastases may increase patients' risk for symptomatic radiation necrosis, a study suggests. |
MedScape
02 November at 10.49 AM
Brazil Child Cancer Deaths Linked to Soy Farming, Study FindsSoy farming has been linked to a rise in child cancer deaths in Brazil, one of the top users of pesticides for protecting crops from disease and pests, according to a study. |
MedScape
02 November at 10.10 AM
Gaza's Only Cancer Hospital Goes Out of ServiceThe only cancer treatment hospital in the Gaza Strip has gone out of service after it ran out of fuel, health officials said on Wednesday. |
MedScape
02 November at 09.33 AM
ADC Shows Survival Benefit in Mets Cervical CancerThe antibody-drug conjugate tisotumab vedotin led to improved outcomes compared with chemotherapy in second- or third-line treatment of recurrent/metastatic cervical cancer. |
MedScape
01 November at 05.15 PM
Pembrolizumab Wins Biliary Tract Cancer IndicationThe new approval is the sixth gastrointestinal indication for the checkpoint inhibitor. |
MedScape
01 November at 03.21 PM
PD-1 Inhibitor Improves Outcomes in NHL SubtypeTreatment with the PD-1 inhibitor toripalimab plus radiation therapy improved outcomes in patients with a subtype of non-Hodgkin lymphoma, new data show. |
MedScape
01 November at 03.01 PM
Assess Risks of Gene Therapy in Follow-Up Study: FDA PanelA panel of advisers to the regulator said on Tuesday Vertex Pharmaceuticals and CRISPR Therapeutics could assess potential safety risks of their sickle cell disease gene therapy after approval. |
MedScape
01 November at 12.08 PM
Stripped Privileges: Alarming Precedent for Community Oncs?A Philadelphia healthcare system has set a new precedent by taking away the in-hospital privileges of five community oncologists, sparking a legal battle. |
MedScape
30 October at 05.09 PM
FDA Approves Toripalimab for Nasopharyngeal CarcinomaThis marks the first approval for toripalimab. |
MedScape
30 October at 01.51 PM
Ocular MALT Lymphoma: Radiation Reduces RelapseWhile relapse is common among patients with this type of lymphoma, those rates decline significantly with the addition of radiation therapy. |
MedScape
30 October at 01.45 PM
Pharma Money to Oncologists Tied to Nonrecommended CareThese findings raise concerns about the influence industry payments may have on oncologists' prescribing practices and quality of patient care. |
MedScape
27 October at 02.48 PM
Experts Question Finding That 70% Cancer Deaths PreventableA new analysis finds most cancer deaths that occur in people younger than 70 could be prevented. But biostatisticians not involved in the research urged caution in interpreting the data. |
MedScape
27 October at 02.27 PM
Induction Chemo Extends Survival in Cervical CancerInduction chemotherapy before definitive chemoradiation improved progression-free and overall survival in locally advanced cervical cancer. |
MedScape
26 October at 04.51 PM
Neoadjuvant, Adjuvant, or Both? The Debate in NSCLC Rages OnThe question of whether to give upfront immunochemotherapy in resectable non–small cell lung cancer, wait until after surgery, or give both remains a hot topic of debate. |
MedScape
25 October at 04.56 PM
'We Finally Made It': Amivantamab Comes of Age in NSCLCData from three trials with the amivantamab in advanced EGFR-mutant NSCLC have yielded "exciting" results with experts hailing the drug as standard of care in various settings. |
MedScape
25 October at 04.55 PM
Investigational ADC Improves PFS in Metastatic Breast CancerDatopotamab deruxtecan led to better progression-free survival and safety compared with standard chemotherapy in patients with metastatic HER-2 negative breast cancer. |
MedScape
25 October at 04.19 PM
Combo Therapy Hailed as Standard for Urothelial CarcinomaFindings from a new analysis found enfortumab vedotin plus pembrolizumab outperformed the current standard of care in locally advanced/metastatic urothelial carcinoma. |
MedScape
25 October at 10.26 AM
7 Key Metrics to Track Oncology Practice SuccessMedscape looked at some of the important metrics that oncology practices track to ensure that their revenue, clinical processes, and patient care procedures shape their success. |
MedScape
25 October at 10.18 AM
FDA OKs Ivosidenib for IDH1-mutated Myelodysplastic SyndromesThe FDA approval was based on a small study, in which 38.9% of patients with relapsed or refractory disease went into complete remission. |
MedScape
24 October at 03.15 PM
'Why Did I Choose This?' Tackling Burnout in OncologyBuilding a sustainable oncology workforce will not be easy, but improving staffing shortages and integrating resilience training can help, experts say. |
MedScape
24 October at 08.59 AM
The Sobering Facts About Alcohol and CancerAn ESMO session highlights the well-known links between alcohol consumption and cancer and calls on healthcare professionals to do more to raise awareness among patients. |
MedScape
23 October at 02.28 PM
Enzalutamide Ups Mets-Free Survival, QoL in Prostate CancerEnzalutamide plus androgen deprivation therapy or alone can extend metastasis-free survival and maintain quality of life in men with prostate cancer facing a high-risk for biochemical recurrence. |
MedScape
23 October at 02.28 PM
Enzalutamide Ups Mets-free Survival, QoL in Prostate CancerEnzalutamide plus androgen deprivation therapy or alone can extend metastasis-free survival and maintain quality of life in men with prostate cancer facing a high-risk for biochemical recurrence. |
MedScape
23 October at 10.58 AM
ICIs Improve pCR Rates in Early ER+/HER2– Breast CancerTwo randomized trials highlighted the benefit of adding immune checkpoint inhibitors to neoadjuvant chemotherapy in patients with early high-risk estrogen receptor–positive, HER2-negative breast cancer. |
MedScape
23 October at 10.56 AM
No Benefit to Adding ICI to Chemo in TNBCThe Michelangelo trial revealed that adding atezolizumab to nab-paclitaxel and carboplatin did not improve 5-year event-free survival in patients with triple-negative breast cancer. |
MedScape
22 October at 03.06 PM
Does Adding Pembro Improve PFS in High-Risk Cervical Cancer?Pembrolizumab improved progression-free survival when added to standard chemoradiotherapy in newly diagnosed, locally advanced cervical cancer, new data show. |
MedScape
22 October at 02.35 PM
Double Good, Triple Therapy Better in Endometrial Cancer?The fast pace of progress in endometrial cancer has taken a step forward with two trials underlining the benefit of immunotherapy plus chemo, while suggesting adding a PARP inhibitor could further boost outcomes. |
MedScape
22 October at 08.55 AM
ALK Inhibitor Alectinib Shows DFS Benefit in Early NSCLCInterim findings from the ALINA trial show improved DFS with alectinib in the adjuvant setting vs chemotherapy in resected stage IB-IIIA NSCLC. But will early DFS results extend to overall survival? |
MedScape
21 October at 05.53 PM
Perioperative Nivolumab Improves EFS in Resectable NSCLCInterim findings from CheckMate 77T show an overall improvement in event-free survival with perioperative nivolumab vs neoadjuvant nivolumab plus chemotherapy only. |
MedScape
21 October at 12.11 PM
Remote Symptom Monitoring in Advanced Cancer Improves QoLBuilding on prior studies, a new trial shows that digital symptom monitoring during cancer treatment detects symptoms early, improves quality of life, and reduces hospital visits. |
MedScape
21 October at 10.01 AM
Long-Term Benefits of Adjuvant Abemaciclib in Breast CancerAdding the CDK4/6 inhibitor to endocrine therapy among women with high-risk early breast cancer continues to show modest but clinically significant benefits 5 years in, compared with endocrine therapy alone. |
MedScape
20 October at 06.55 PM
Observation, Not Radiotherapy, After Radical ProstatectomyThe investigators observed no benefit to adjuvant radiotherapy after radical prostatectomy in patients with prostate cancer in the phase 3 RADICALS-RT trial. |
MedScape
20 October at 03.51 PM
Fasting During Breast Cancer Chemo Improves Quality of LifeShort-term fasting around the time of chemotherapy is a promising supportive therapy during breast cancer chemotherapy that may enhance quality of life and prevent fatigue. |
MedScape
20 October at 03.06 PM
Can Some Patients With Esophageal Cancer Avoid Surgery?About one third of patients with esophageal cancer who have a compete response to neoadjuvant chemoradiotherapy may be able to avoid surgery. However, one expert questioned the study design. |
MedScape
20 October at 09.45 AM
Active Surveillance Preferred in Low-Risk Prostate CancerWhen informed about treatment options, most men with low-risk prostate cancer chose active surveillance instead of active therapy in a recent Italy-based analysis. |
MedScape
19 October at 01.36 PM
Predicting Recurrence in Rectal Cancer Watchful WaitingInvestigators reported that the Immunoscore biopsy, which quantifies immune cell tumor infiltration, is a strong predictor of recurrence during watchful waiting for rectal cancer. |
MedScape
19 October at 08.58 AM
New Trials in Colorectal Cancer: Could Your Patient Benefit?Maybe one of your patients can join a new clinical trial in colorectal cancer. |
MedScape
18 October at 12.41 PM
Navigating Key Endpoints in Oncology Clinical TrialsHere's a guide to understanding endpoints you will likely encounter in cancer clinical trials. |
MedScape
17 October at 05.16 PM
FDA OKs Neoadjuvant/Adjuvant Pembrolizumab in NSCLCThe approval allows for continuous immunotherapy treatment around surgery for resectable non-small cell lung cancer. |
MedScape
17 October at 01.18 PM
Is Short-Term ADT Good Enough in High-Risk Prostate Cancer?Continuing ADT beyond 6 months does not improve outcomes in men with high-risk localized prostate cancer also receiving brachytherapy and external beam radiation therapy, new research suggests. |
MedScape
16 October at 02.40 PM
When to Treat DLBCL With Radiotherapy?Although radiation has become important in the treatment of diffuse large B cell lymphoma (DLBCL), radiologists highlight some the limitations of this approach. |
MedScape
16 October at 02.24 PM
FDA Approves Nivolumab for Resected Stage IIB/C MelanomaThe new approval expands the melanoma indication for nivolumab to earlier-stage disease. |
MedScape
16 October at 12.11 PM
These Factors Predict Shorter Time to PSA FailureA new study identifies three factors associated with PSA failure in men with nonmetastatic unfavorable-risk prostate cancer, revealing who may benefit from treatment escalation. |
MedScape
13 October at 09.53 AM
Doublet Therapy Ups Survival in Metastatic Prostate CancerThe use of doublet therapy has increased survival by 6 months, on average, in men with de novo metastatic castration-sensitive prostate cancer, according to Swedish registry data. |
MedScape
12 October at 04.56 PM
FDA OKs Drug Combo in BRAF V600E-Mutated Metastatic NSCLCThe single-arm approval study reported an objective response rate of 75% among treatment-naive patients. |
MedScape
12 October at 11.10 AM
Survival on the Upswing in Multiple MyelomaHematologists are heralding a new era in multiple myeloma. Experts discuss how times have changed. |
MedScape
12 October at 08.48 AM
Quality of Life, Access Top Priorities in Cancer CareOverall, cancer clinicians, patient advocates, researchers, and others rated patient-centered factors, especially quality of life, as top priorities in delivering value-based cancer care, a new survey shows. |
MedScape
11 October at 02.41 PM
What the First Authorized DNA Cancer Risk Test Can Tell YouThe Invitae test system aims to assess a person's risk of developing certain cancers but is not intended as a cancer screening tool, the FDA says. |
MedScape
11 October at 02.41 PM
Assessing Cancer Risk? Here's What the New DNA Test Can DoThe Invitae test system aims to assess a person's risk of developing certain cancers but is not intended as a cancer screening tool, the FDA says. |
MedScape
11 October at 10.55 AM
ESMO 2023: A Wealth of New Data Across Cancer TypesThe march of immunotherapy into a wider range of malignancies, as well as the smarter use of chemotherapy and novel targeted drugs, will be among the key highlights at the ESMO Congress 2023. |
MedScape
10 October at 11.36 AM
Breast Reconstruction Postmastectomy: What Matters Most?A survey sheds light on what women value most when it comes to post-mastectomy breast reconstruction, findings that could lead to more patient-centered care. |
MedScape
09 October at 01.45 PM
DART Can Limit Toxicities in Head, Neck CancerDaily adaptive radiotherapy minimized radiation exposure to salivary glands and led to fewer acute toxicities among patients with head and neck cancer. |
MedScape
09 October at 12.26 PM
ctDNA Pre-Radiation Predicts Oligometastatic NSCLC SurvivalMeasuring ctDNA levels before radiotherapy predicted PFS and overall survival, and can help determine the patients most likely to benefit from consolidation radiotherapy vs systemic therapy. |
MedScape
09 October at 11.07 AM
'Reassuring' Data on Partial-Breast Radiation in Early BCA 10-year follow-up analysis found that partial-breast and reduced-dose radiation therapy were noninferior to full-breast radiation therapy among women with early breast cancer. |
MedScape
06 October at 12.45 PM
Higher-Dose Radiotherapy Can Improve Survival in SCLCPatients with limited-stage small cell lung cancer demonstrated better overall and progression-free survival on higher-dose thoracic radiotherapy vs standard treatment, new data show. |
MedScape
06 October at 11.31 AM
Does Surgery Improve Survival in Metastatic Breast Cancer?In a meta-analysis, researchers concluded that surgery does not improve survival and "should not be routinely offered to patients with metastatic disease." |
MedScape
06 October at 10.52 AM
Head, Neck Cancer Regimen Saves Time When Resources LimitedA randomized controlled trial conducted in 10 low- to middle-income countries showed that 11.5 days could be safely shaved off a conventional fractionation schedule at no cost regarding outcomes. |
MedScape
06 October at 10.26 AM
FDA Panel Says Amgen Lung Cancer Drug Data Cannot Be Relied onAdvisers to the US Food and Drug Administration on Thursday found that data from a late-stage trial of Amgen's Lumakras could not be relied on. |
MedScape
05 October at 02.18 PM
MOC Opposition Continues to Gain Momentum as ASH Weighs InThe American Society of Hematology (ASH) urged changes to the MOC process in a recent letter to the ABIM. ASCO is currently surveying members about their MOC experience. |
MedScape
05 October at 11.03 AM
CT Simulation Not Needed in Palliative Radiotherapy PlanningInvestigators say using diagnostic CT, rather than CT simulation, for palliative radiotherapy planning brings faster pain relief to patients and saves providers' time. |
MedScape
05 October at 09.00 AM
NCCN Survey Shows Ongoing Chemo Drug ShortagesNearly 90% of NCCN member institutions that responded to a September survey reported a shortage of at least one anticancer agent. |
MedScape
04 October at 05.04 PM
High-Dose Radiation After Mastectomy Could Be 'Game Changer'Women with breast cancer who had breast reconstruction following mastectomy did as well or better from shorter bursts of higher-dose radiation compared with conventional therapy, new data reveal. |
MedScape
04 October at 04.26 PM
SABR May Defer Systemic Therapy in This Breast Cancer TypeStereotactic ablative body radiotherapy could delay the need for changes in systemic therapy in postmenopausal womenwith oligoprogressive luminal ER-positive breast cancer, new data show. |
MedScape
04 October at 04.08 PM
We Know Exercise Prevents Cancer. A New Study Tells Us WhyA small study in Lynch syndrome patients may be the first to reveal immunological reactions to physical activity. |
MedScape
04 October at 02.11 PM
Vaginal Dilation May Lower Stenosis Risk in Cervical CancerNew data show that sexual intercourse and vaginal dilation can lower the risk for stenosis following chemoradiation for cervical cancer. |
MedScape
04 October at 11.17 AM
Reducing Cognitive Impairment From SCLC Brain MetastasesStereotactic radiosurgery was better at preventing loss of verbal recall function at 3 months than whole-brain radiation therapy, the current standard of care for patients with brain metastases from small cell lung cancer. |
MedScape
04 October at 11.16 AM
Short-Course SBRT: Standard of Care in Prostate Cancer?For patients with low and favorable intermediate-risk prostate cancer, stereotactic body radiation therapy delivered in five fractions provided similar 5-year disease control as conventional, higher-dose external-beam radiation. |
MedScape
04 October at 09.44 AM
Court Tosses $223.8 Million Verdict Against J&J in Talc Cancer CaseA New Jersey appeals court on Tuesday threw out a $223.8 million verdict against Johnson & Johnson that a jury had awarded to four plaintiffs. |
MedScape
04 October at 09.42 AM
Amgen's Late-Stage Data for Lung Cancer Drug 'Not Adequate'The FDA staff reviewers have said Amgen's late-stage study might not be sufficient to confirm the effectiveness for its lung cancer drug, as the firm pursues a traditional nod for the treatment. |
MedScape
04 October at 09.34 AM
USPSTF Should Reconsider Rec to Lower Mammogram Age: ExpertsExperts discuss how the change from starting mammography screening at age 40 instead of 50 will come with few benefits and big potential harms. |
MedScape
03 October at 03.35 PM
Takeda Announces Voluntary Withdrawal of Lung Cancer TherapyThe company said on Monday it will voluntarily withdraw its lung cancer therapy from the US after it failed to meet the main goal in a late-stage study. |
MedScape
03 October at 01.55 PM
What Is the Future for Multicancer Early Detection Tests?These tests would not replace routine screening but help screen patients with no symptoms or nonspecific signs for cancers for which we could not otherwise screen, says an oncologist. |
MedScape
03 October at 11.25 AM
Salvage Option to Replace Transplant in RR Hodgkin Lymphoma?A chemoimmunotherapy and radiation combination without autologous stem cell transplant produced high response rates in children and young adults with low-risk relapsed/refractory Hodgkin lymphoma. |
MedScape
02 October at 10.11 AM
Drug-Induced Hyperglycemia More Common in Clinical PracticeA retrospective study found significantly higher rates of hyperglycemia among patients with metastatic breast cancer treated with alpelisib in clinical practice compared with clinical trials. |
MedScape
02 October at 09.30 AM
AbbVie's Blood Cancer Combo Therapy Fails in Late-Stage StudyAbbVie has said a late-stage study of its experimental combination therapy failed to meaningfully increase the survival rate of patients without the disease worsening. |
MedScape
29 September at 02.05 PM
ADC Toxicities: The Price You Pay for EfficacyUnderstanding the toxicities associated with antibody-drug conjugates could help oncologists develop strategies to diminish adverse events that arise during treatment with these powerful agents |
MedScape
29 September at 09.16 AM
Cost Concerns Lead to Cancer Treatment Delays, NonadherenceHospital-based financial navigators may help cancer patients negotiate the intricacies of insurance coverage, experts suggest. |
MedScape
28 September at 05.23 PM
Dispelling Misconceptions About Sickle Cell DiseaseAffecting more than 20 million people globally and 100,000 people nationwide, SCD is the most common inherited blood disorder in the United States. |
MedScape
28 September at 09.17 AM
These Adverse Events Linked to Improved Cancer PrognosisCutaneous immune-related adverse events are associated with a better prognosis among patients with cancer who receive immune checkpoint inhibitors, new research suggests. |
MedScape
28 September at 09.04 AM
EU Ban on PFAS Would Halt Drug Production: Pharma LobbyEuropean drugmakers warned that a proposed complete ban on substances known as PFAS or 'forever chemicals' would render medicine production in the region impossible, part of a high-stakes wrangle between manufacturers and environmental regulators. |
MedScape
27 September at 03.54 PM
FDA Approves Bosutinib for Children With CMLThe agency approved the tyrosine kinase inhibitor for pediatric patients with chronic phase Ph+ chronic myelogenous leukemia that is newly diagnosed or resistant or intolerant to prior therapy. |
![]()
Medical xPress
05 July at 07.10 AM
When it comes to male life expectancy, nature and nurture work togetherAlthough the simple biological fact (nature) of being born male increases boys' and men's overall health risks, the behavioral choices (nurture) they make are at least as important. This means that trans men and others who identify as men, while not biologically male, may also experience the behavioral disadvantages of being male. |
![]()
Medical xPress
05 July at 06.50 AM
Study explores the link between stock market fluctuations and emergency room visits in ChinaThe advent of computerized trading and fintech platforms has made investing in stocks easier and more accessible to individuals worldwide. This has led to an increase in stock market participation in many countries, including China. |
![]()
Medical xPress
30 June at 07.40 AM
Decision to offer sedation for often-painful IUD insertion is 'groundbreaking,' health experts sayIntrauterine devices (IUDs) are a highly effective and long-lasting form of birth control placed in the uterus. Research shows that many people who get IUDs experience moderate to intense pain during the insertion. But it wasn't until recently that providers began to acknowledge this and do something about it. |
![]()
HealthDay
27 June at 03.19 PM
Immunoglobulin Replacement Therapy Beneficial for Blood CancersImmunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated antimicrobial use among real-world patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin lymphoma (NHL), according to a study published online June 21 in Blood Advances.Jacob D. Soum |
Medpage Today
26 June at 04.59 PM
When Was the Last Time You Really Talked With Your Patient?My 10 o'clock patient's name is Maria*. Her chart has three "health maintenance" flags that are bright red, indicating that she is more than 3 years overdue for a mammogram, more than 6 years overdue for a Pap smear, and has... |
Medpage Today
23 June at 09.21 PM
Novel Triple-Hormone Agonist Boosts Beta-Cell Function in T2DORLANDO -- An investigational triple-hormone receptor agonist improved metabolic profiles of people with obesity with or without type 2 diabetes, an exploratory biomarker analysis of a phase II trial found. After 36 weeks... |
Medpage Today
22 June at 06.00 PM
Fenofibrate Slows Diabetic Retinopathy ProgressionORLANDO -- The cholesterol drug fenofibrate reduced progression of early eye disease among diabetes patients, the LENS trial showed. The fibrate reduced progression of early diabetic retinopathy or maculopathy by a relative... |
Medpage Today
22 June at 06.00 PM
Preventing Surgical-Site Infections; Drugs Go Head to Head for Ischemic StrokeTTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... |
![]()
Medical xPress
22 June at 05.20 PM
Lawsuit could challenge trust in Ozempic and other popular weight loss drugsThe manufacturers of the most popular weight loss drugs are being challenged in court. |
![]()
HealthDay
21 June at 03.38 PM
Overall Prevalence of Being Up-to-Date With Lung Cancer Screening Is LowThe overall prevalence of up-to-date (UTD) lung cancer screening (LCS) was low in 2022, with prevalence increasing with age and number of comorbidities, according to a study published online June 10 in JAMA Internal Medicine.Priti Bandi, Ph.D., from the American Cancer Society in Atlanta, and colleagues estimated the contemporary preval |